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Abstract: BACKGROUND. A wide range of novel psychoactive substances (NPS) is regularly searched and discussed 
online by web-based drug enthusiasts (i.e. the e-psychonauts). Among NPS, the range of synthetic cannabinoids (SC; 
‘Spice’) currently represents a challenge for governments and clinicians. 
METHODS. Using a web crawler (i.e. the NPS.Finder®) the present study aimed at assessing psychonauts’ fora/platforms 
to better understand the online mentions of SC. 
RESULTS. The open-web crawling/navigating software identified here some 1,103 synthetic cannabinoids. Of these, 863 
molecules were not listed in either the international or the European NPS databases. 
CONCLUSIONS. A web crawling approach helped here in identifying a large range of unknown SC likely to possess a 
misuse potential. Most of these novel/emerging molecules are still relatively unknown. This is a reason for concern; each 
of these analogues potentially presents with different toxicodynamic profiles and there is a lack of docking, preclinical, and 
clinical observations. Strengthening multidisciplinary collaboration between clinicians and bioinformatics may prove useful 
in better assessing SC-associated public health risks. 
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1. INTRODUCTION
1.1 Background
The web may play a pivotal role in the ‘life cycle’ of NPS. 
[1] After being synthesized in illegal chemical laboratories,
NPS are then made available through e-commerce to
interested customers. These customers include the e-
psychonauts, [2] whose primary aim is discovering and
experiencing with the effects of new chemical compounds. [3]
[4] e-Psychonauts share their experiences on a range of
multilingual, specialized, dedicated web fora/blogs, [5] [6]
hence facilitating information spreading to other consumers of
the index new psychoactive molecule. [2] [3]
 Within this scenario, synthetic cannabinoids (SC), known 
also as synthetic cannabimimetics or synthetic cannabinoid 
receptor agonists (SCRAs), constitute one of the main class of 
new/novel psychoactive substances (NPS). Despite the term 
‘novel’, the first products were synthesized by pharmaceutical 
industries between the '70s and '80s, after noticing the 
potential analgesic, antiemetic and narcotic effects of the 
endocannabinoid system. [7] 
 Since the first SC identification in the drug market in 2008, 
numbers of cannabinoids available have grown steadily. 
According to both the European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA) and the United Nations 
Office on Drugs and Crime (UNODC), SC are the most 
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typically seized NPS reported in Europe and elsewhere. [8] 
[9] [10] [11] [12]
Whilst being labelled as ‘not for human consumption’ or
as ‘laboratory products’, [13] [14] [15] SC are usually made 
available in colourful packages with different names (e.g. 
‘Spice’, ‘K2’, ‘Kronic’, ‘Voodoo’). SC use has been 
associated with vulnerable subjects, including inmates and 
homeless people. [16] 
 Because of their activity on CB1 receptors, over the last 
decade SC have at times been interpreted as the ‘legal 
substitutes’ of cannabis. [8] Indeed, they show higher CB1 
binding affinity levels than (–)-trans-Δ9-tetrahydrocannabinol 
(THC), [8] though multiple interactions with remaining 
classes of receptors have also been commented. [14] Hence, 
SC present with a range of unpredictable clinical effects, 
which have included severe ill-health events [17] and 
fatalities.  [9] [10] [18] 
 Clinicians and health professionals typically perceive their 
NPS-, including SC-, related knowledge levels as inadequate. 
[19] Indeed, the pace at which scientific evidence is updated
cannot withstand the constant and rapid entry into the market
of further NPS molecules.
1.2 Aims 
The aim of the current research was to: (a) identify and 
categorize the number of SC molecules collected by a 
dedicated web crawler (i.e. the NPS.Finder®) from a range of 
psychonaut, NPS-related, online sources; (b) compare the 
NPS.Finder® SC list with related findings from the UNODC 
and the EMCDDA. 
2. METHODS
2.1 Search strategy 
To facilitate the process of early recognition of emerging 
psychoactive molecules, a crawling/navigating software (i.e. 
the ‘NPS.Finder®’) was designed to automatically scan the 
open/surface web for new/novel/emerging NPS (for a 
thorough description of both web crawling and data cleaning 
activities please refer to recently published studies [5] [6]). 
This software was designed to map on a 24/7 basis the large 
variety of psychoactive molecules mentioned within a range 
of popular online psychonauts websites/fora (Appendix 1). 
First, a number of proper piloting searches were performed 
using a range of key words, including: NPS; novel 
psychoactive substances; new psychoactive substances; 
emerging psychoactive substances; drugs online; buy new 
substances; psychonauts, drug forums; psychoactive products; 
synthetic cannabinoids; synthetic cathinones; psychedelic 
phenethylamines; novel stimulants; synthetic opioids; 
tryptamine derivatives; phencyclidine-like dissociatives; 
piperazines; GABA-A/B receptor agonists; prescribed 
medications; psychoactive plants; psychoactive herbs; and 
image- and performance-enhancing drugs. Any new website 
of interest was added to the list. Afterwards, a range of 
specific automatic web crawler activities were carried out 
from 14 November 2017 to 31 May 2019. Although the 
language most typically used in these websites was English, 
further languages analyzed by the NPS.Finder® included: 
Dutch, French, Turkish, Swedish, Spanish, German, Russian, 
and Italian. 
 Resulting data were collected using Python-language web 
crawlers, one for each site listed, through daily scanning 
activities. Emerging findings were first stored in a temporary 
virtual storage area and then in an MYSQL database which 
presented with an SSL security protocol. All data were 
encrypted with asymmetric cryptographic procedures. 
2.2 Data collection 
 NPS.Finder® extracted a range of NPS-related 
information, including chemical and street names; chemical 
formula; three-dimensional images; and anecdotally reported 
clinical/psychoactive effects. These data were automatically 
stored in an online, restricted access/password-controlled 
database located within firewall protected, highly secure, and 
consistently performing servers. 
2.3 Data screening and duplication check 
 With the help of an ‘ad hoc’ check control panel, all data 
were manually and carefully analyzed by 4 
medically/psychiatrically trained professionals (i.e. FN; DA; 
CZ; and LG). In the case of data interpretation issues, these 
were resolved by consultation with FS, AG, JC and AV. 
 The web crawler-identified SC molecules’ denominations 
were first searched in Medline/PubMed [20] and in 
Google®/Google® Scholar. [21] [22] A further screening was 
carried out with the help of Pubchem; [23] ChemSpider®; 
[24] and ChEMBL. [25] [26] [27] To avoid duplications, the
International Union of Pure and Applied Chemistry (IUPAC)
denomination was used for each molecule. In this way, a full
assessment and editing of each NPS.Finder® data entry was
carried out and the range of unique SC molecules here
commented was identified (please note that the complete and
regularly updated list of NPS identified by the web-crawler
activities is freely available at
https://npsfinder.com/home.php).
3. RESULTS
With the help of the web crawler activities, some 5922
substances were here identified. After proper data screening 
and duplication check completion, some 4204 unique NPS 
molecules were included in the database and 1718/5922 
(29.01%) remaining molecules were found to be false 
positives or duplicates. Of these, 1103 SC were collected, 
representing 26.2% (CI 95%: 25.9-27.6%) of the total number 
of molecules, and the second largest group after psychedelic 
phenethylamines (30.1%; CI 95%: 28.7-31.5%).  
 Conversely, by 13th June 2019 the UNODC listed some 
286 SC and, by 1st April 2019, the EMCDDA database 
included 193 different SC. Some 863 SC (78.2%; CI 95%: 
75.1-80.6%) were identified only by the NPS.Finder®, and 
182 SC (16.5%; CI 95%: 14.4-18.8%) were common to all 
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three databases. Finally, some 52 molecules were mentioned 
in either the EMCDDA or the UNODC lists but had not been 
identified by the NPS.Finder® web crawler (Table 1). Hence, 
the three databases identified an overall number of 1155 
synthetic cannabinoids (Appendix 2). 
 These 1155 SC were here further categorized with a 
hierarchical approach (i.e. categories 1; 2a; 2b; 3), as follows: 
1) SC listed by the EMCDDA and/or by the UNODC; 292 
(25.3%, CI 95%: 22.8-27.8%) molecules were included; 2a) 
SC which were not listed by either the EMCDDA or the 
UNODC, but which  are scheduled, and/or for which evidence 
levels of abuse have already been reported in peer-reviewed 
papers; 94 molecules (8.1%, CI 95%: 6.6-9.7%); 2b) SC 
commented on the psychonaut websites/fora; 767 (66.4%, CI 
95%: 63.7-69.1%); 3) SC used as laboratory research 
products/analytical references and/or studied in preclinical or 
animal research; 2 molecules (0.1%, CI 95%: 0.0-0.4%) 
(Figure 1). 
 
4. DISCUSSION  
 The present paper provides unique and unprecedented 
figures in terms of overall numbers of synthetic cannabinoids, 
collected using an innovative and automatic search strategy. 
Consistent with previous observations from our group, [5] the 
NPS.Finder® database identified here a quantitative level of 
SC which is about 5-fold higher than that identified by both 
the UNODC and the EMCDDA. Although present results, 
highlighting a strong interest by psychonauts towards SC, do 
not necessarily confirm in any possible way these molecules’ 
levels of use, they can help in explaining levels of concern 
relating to the current NPS scenario, which well includes SC. 
[28] [29] 
 Indeed, out of the 1155 SC overall number identified by 
the 3 databases, NPS.Finder® captured 1103/1155 (95.5%) of 
them, a better performance than both the UNODC (286/1155; 
24.8%) and the EMCDDA (193/1155; 16.7%). There might 
be different reasons behind these inconsistencies in data 
reporting. First, both the UN and EU agencies collect in their 
databases only those molecules which are detected/seized and 
properly analyzed. The EMCDDA reports on 28 EU countries 
only, whilst both the UNODC database and the psychonauts’ 
entries may better reflect the global situation. Furthermore, 
NPS.Finder® carried out here a range of open web crawling 
identification activities focusing on a large range of 
psychonaut-based, specialized, multilingual, sources with a 
specific focus on NPS. Although one could argue that 
discussing a molecule on the web is not, per se, an indication 
that the index molecule is being/will be ingested by interested 
individuals, the current SC list was generated whilst crawling 
only on the open web. In other words, this may well reflect 
the level of SC-related information which may be accessible 
to anyone, including vulnerable children and adolescents, 
without the need of using sophisticated search techniques or 
downloading deep web/darknet ad hoc browsers. [30] 
 Notably, roughly 1 out of 4 of the current 1155 SC is 
currently under surveillance by either EMCDDA or UNODC. 
Those SC under surveillance are likely to present with more 
convincing evidence of misuse compared with remaining 
molecules, resulting in high levels of concern by clinicians 
and policymakers. [12] Nonetheless, there are further 94 SC 
which have been mentioned in the literature [31] [32] [33] 
[34] but which are currently not listed by EMCDDA nor 
UNODC. With the introduction of new control laws, some of 
these compounds have recently been scheduled, [15] with 
their purchase now being arguably more problematic. [35] 
Finally, roughly 2/3 of the 1155 SC were here mentioned only 
by the psychonauts’ fora. Some of these SC might currently 
be at their ‘life cycle’ early stages and it is possible that some 
of them will become more popular in the future. [1] [9] [36] 
Indeed, reports on new drugs are likely to emerge 
considerably later than their first appearance in e-
psychonauts’ discussions. [36] [37] 
4.1 Pharmacological and clinical pharmacological 
considerations 
 Although the evidence base for most SC molecules here 
mentioned is lacking, they are likely to act as partial/full 
agonists, and with different affinity levels, at the CB1 
receptors. Nonetheless, SC may act as well on both 5-HT2A 
and NMDA receptors, [38] hence the vast range of ill-health 
consequences associated with these molecules. [5] Moreover, 
there are difficulties in identifying them with analytical 
chemistry techniques. [39] A clear understanding of the 
clinical toxicity of each compound is at present problematic. 
Although the in vitro pKi values/binding affinities for some 
SC molecules are already available, [40] consistent with what 
it has been suggested for novel synthetic opioids this may not 
provide enough information about the relative in vivo 
potency. [41] In fact, there might be variable effects on 
receptors, which could potentially give rise to a great diversity 
of intracellular consequences following the administration of 
different analogues with apparently similar 
pharmacodynamics. [42] Furthermore, as highlighted using a 
molecular docking model, some substances are too 
structurally similar for the scoring function to distinguish 
between different similar molecules. [43] [44] 
4.2 Use of the ‘big data’ analysis in understanding changes 
in drug scenarios 
 Since the recreational drug business has moved from face-
to-face to an anonymous, web-based, marketplace [30] the 
best approach to understand the current drug scenario is to 
analyze the information/data made available by the 
consumers/e-psychonauts themselves. [37] However, the 
analysis of this data requires the management of ‘high-
volume, high-velocity, and high-variety’ [45] range of 
modifications in the NPS market, which makes it a convincing 
example of ‘big data’.  Over the past few years, the use of big 
data analytics has been successfully used in a range of health-
related areas, including the early identification of influenza 
epidemics. [46] [47] [48] There are however methodological 
limitations with this approach, [45] [49] and these are related 
to the reliability of web-based collected data. [49] Conversely, 
when the amount of information overtakes the capacity of 
traditional research methods, the use of big data analytics can 
help to provide a nearly real-time update. [50] 
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 The use of automatic software such as the NPSfinder® has 
allowed here both scanning and identification activities of a 
constant flow of drug-related data. To improve accuracy and 
provide a thorough evaluation of SC use, however, further 
research should focus on an integrative model in which web-
based analyses will be combined with more traditional 
identification methods. [49] Understanding the 
pharmacological characteristics/potency of those SC 
molecules which are of appeal for potential consumers will 
hopefully help in both predicting SC diffusion and reducing 
the existing gap in knowledge between the web-based 
consumers and clinicians, hence facilitating the planning of ad 
hoc prevention strategies.  
4.3 Limitations 
 During the current phase of its development, the 
NPS.Finder® has crawled on the open web only. Future 
studies by our group will be expanding drug searches on less 
accessible areas of the web, such as the deep web and the 
darknet. [30] A qualitative/netnographic approach [51] [52] 
will be needed as well, to better assess the possible 
psychonauts’ preference between SC analogues and their 
motivation for use. Since previous studies have highlighted 
their importance in NPS-based studies, [53] next 
NPS.Finder®-based research will need to focus as well on 
further languages, e.g. Chinese, Japanese and Arabic. Finally, 
some SC commented online may have been missed by our 
search software. Nonetheless, to the best of our knowledge, 
the most comprehensive literature dataset of SC has been 
provided here. 
CONCLUSIONS 
 The web crawler activities may well possess the potential 
to identify a wide range of novel/previously undescribed NPS, 
including SC. The literature base regarding these molecules is 
limited in terms of acute and long-term effects, adverse 
effects, abuse potential, and manufacturing/distribution in 
both the virtual and real markets. Indeed, future in silico, in 
vitro, and in vivo studies could provide important findings. 
Furthermore, it is deemed here essential to monitor the real-
life scenarios through drug checking in interdiction, drug 
outpatient clinics and in critical care settings. Better levels of 
misusing drugs’ clinical pharmacological-related knowledge 
are needed so that properly tailored management/treatment 
strategies and guidelines can be drawn up and made available. 
Finally, strengthening multidisciplinary collaboration 
between clinicians and bioinformatics may prove useful in 
better assessing the SC-associated public health risks. 
 
SUPPLEMENTARY MATERIAL 
 The list of the open psychonauts’ websites scanned by 
NPS.Finder® is provided in Appendix 1.  
 The list of all synthetic cannabinoids collected in our 
database is provided in Appendix 2. 
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Table 1 Number of SCRAs in the NPS.Finder®, UNODC, and EMCDDA databases. The number of SCRAs shared 
between the three databases is also presented, as follows: I= total number of molecules included in the NPS.Finder 
database; II= total number of molecules included in the UNODC list; III= total number of molecules included in the 
EMCDDA list; IV= number of molecules included in all three lists; V= number of molecules included in both 
NPS.Finder and UNODC lists, but not  in the EMCDDA one; VI= number of molecules included in the NPS.Finder and 
EMCDDA lists, but not in UNODC one; V= number of molecules included in both UNODC and EMCDDA lists, but not 
in the NPS.Finder one; VIII = number of molecules included only in the NPS.Finder list, IX = number of molecules 
included only in the UNODC list; X = number of molecules included only in the EMCDDA list; XI: total number of 
unique SC molecules identified. 
 DATABASE Number of SCRAs 
I NPS.Finder® total 1103 
II UNODC total 286 
III EMCDDA total 193 
IV NPS.Finder® and UNODC and EMCDDA 182 
V NPS.Finder® and UNODC 54 
VI NPS.Finder® and EMCDDA 4 
VII UNODC and EMCDDA 5 
VIII NPS.Finder® alone 863 
IX UNODC alone 45 
X EMCDDA alone 2 
XI Total number of unique molecules 1155 
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Figure 1 categorization of 1,155 SC: category 1)SC listed by the EMCDDA and/or by the UNODC: 292 
molecules; 2a) SC which are already scheduled, and/or for which evidence levels of abuse have 
already been reported in peer-reviewed papers, but which are not listed by either the EMCDDA or the 
UNODC: 94 molecules; 2b) SC commented on the psychonauts’ websites/for a: 767 molecules; 3) 
SC used as laboratory research products/analytical references and/or studied in preclinical or animal 
research: 2 molecules. 
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Appendix 1: List of websites monitored by the NPS.Finder® web crawler during the time frame November 
2017-May 2019; surface web only.
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Appendix 2 List of SC mentioned by the psychonauts and identified either through the web crawler activities or presented in the EMCDDA and/or 
UNODC lists, for a total of 1,155 unique molecules. The table reports names of all SC; their alternative and IUPAC denominations; if they are present (Y) 
in the UNODC, EMCDDA and NPSfinder® lists and their categorization (i.e. Categories: 1) SC listed by the EMCDDA and/or by the UNODC: 292 
molecules; 2a) SC which are already scheduled, and/or for which evidence levels of abuse have already been reported in peer-reviewed papers, but 
which are not listed by either the EMCDDA or the UNODC: 94 molecules; 2b) SC commented on the psychonauts’ websites/fora: 767 molecules; 3) SC 
used as laboratory research products/analytical references and/or studied in preclinical or animal research: 2 molecules. 
 NAME OTHER NAMES IUPAC denomination UNODC EMCDDA NPSFinde   
1 ([1,1'-BIPHENYL]-2-YL)(1-PENTYL-1H-INDOL-3-YL)METHANONE N/A C26H25NO; ([1,1′-Biphenyl]-2-yl)(1-pentyl-1H-indol-3-yl)methanone . . Y  










Y . .  
5 (1-PENTYL-1H-INDAZOL-3-YL)(PIPERAZIN-1-YL)METHANONE N/A C17H24N4O; (1-pentyl-1H-indazol-3-yl)(piperazin-1-yl)methanone Y . .  
6 (1-PENTYL-1H-INDOL-3-YL)(PYRIDIN-3-YL)METHANONE N/A C19H20N2O; (1-pentyl-1H-indol-3-yl)(pyridin-3-yl)methanone Y . .  













. . Y  
10 (2-ADAMANTYL) 5CL-APINACA N/A C23H30ClN3O; N-(Adamantan-2-yl)-1-(5-chloropentyl)-1H-indazole-3-
carboxamide 






. . Y  
12 (2-PENTYL) JWH-018 N/A C24H23NO; (Naphthalen-1-yl)[1-(pentan-2-yl)-1H-indol-3-
yl]methanone 
. . Y  
13 (2H-INDAZOLE) APINACA N/A C23H31N3O; N-(Adamantan-1-yl)-2-pentyl-2H-indazole-3-carboxamide . . Y  
14 (2MB) JWH-018 N/A C24H23NO; [1-(2-Methylbutyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 





. . Y  
16 (3-PENTYL) JWH-018 N/A C24H23NO; (Naphthalen-1-yl)[1-(pentan-3-yl)-1H-indol-3-
yl]methanone 










. . Y  




































. . Y  
26 (5-METHYL-6-(2-MORPHOLINOETHYL)-6H-THIENO[2,3-
B]PYRROL-4-YL)(1-PROPYL-1H-INDOL-2-YL)METHANONE 
US 2013/0178453 #11 C25H29N3O2S; {5-Methyl-6-[2-(morpholin-4-yl)ethyl]-6H-thieno[2,3-
b]pyrrol-4-yl}(1-propyl-1H-indol-2-yl)methanone 
. . Y  
27 (5-METHYL-6-PROPYLTHIENO[2,3-B]PYRROL-4-YL)-(6-
PROPYLTHIENO[2,3-B]PYRROL-5-YL)METHANONE 
US 2013/0178453 #83 C20H22N2OS2; (5-Methyl-6-propyl-6H-thieno[2,3-b]pyrrol-4-yl)(6-
propyl-6H-thieno[2,3-b]pyrrol-5-yl)methanone 





. . Y  
29 (6-ETHYLTHIENO[2,3-B]PYRROL-5-YL)-(1-PROPYLPYRROLO[2,3-
B]PYRIDIN-3-YL)METHANONE 
US 2013/0178453 #34 C19H19N3OS; (6-Ethyl-6H-thieno[2,3-b]pyrrol-5-yl)(1-propyl-1H-
pyrrolo[2,3-b]pyridin-3-yl)methanone 
. . Y  
30 (6-ETHYLTHIENO[2,3-B]PYRROL-5-YL)-[1-(OXAN-4-
YLMETHYL)INDOL-3-YL]METHANONE 
US 2013/0178453 #16 C23H24N2O2S; (6-Ethyl-6H-thieno[2,3-b]pyrrol-5-yl){1-[(oxan-4-
yl)methyl]-1H-indol-3-yl}methanone 










. . Y  
33 (6AR,10AR)-6,6,9-TRIMETHYL-3-(2-METHYLOCTAN-2-YL)-
6A,7,8,10A-TETRAHYDRO-6H-DIBENZO[B,D]PYRAN-1-AMINE 
N/A C25H39NO;  (6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-
6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-amine 











. . Y  
36 (6AR,10AR)-6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-
TETRAHYDRO-6H-DIBENZO[B,D]PYRAN-1-AMINE 
N/A C21H31NO;  (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,10a-
tetrahydro-6H-dibenzo[b,d]pyran-1-amine 
. . Y  
37 (ALLYL) JWH-018 N/A C22H17NO; (Naphthalen-1-yl)[1-(prop-2-en-1-yl)-1H-indol-3-
yl]methanone 
. . Y  
38 (AZEPANE) AB-005 N/A C23H32N2O; (1-(1-methylazepan-3-yl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
39 (AZEPANE) AM-1220 N/A C26H26N2O; [1-(1-Methylazepan-3-yl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
Y Y Y  
40 (BENZYL) JWH-018 N/A C26H19NO; (1-Benzyl-1H-indol-3-yl)(naphthalen-1-yl)methanone . . Y  
41 (BENZYL) PB-22 1-(Phenylmethyl)-1H-indole-3-carboxylic 
acid 8-quinolinyl ester 
C25H18N2O2; Quinolin-8-yl 1-benzyl-1H-indole-3-carboxylate Y . Y  
42 (C11)-CP-47,497 N/A C25H42O2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(2-methyldodecan-2-
yl)phenol 
. . Y  
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43 (C4) JWH-210 N/A C25H25NO; (1-Butyl-1H-indol-3-yl)(4-ethylnaphthalen-1-yl)methanone . . Y  
44 (C4) ORTHO-RCS-4 RCS-2-C4;  C20H21NO2; (1-Butyl-1H-indol-3-yl)(2-methoxyphenyl)methanone Y . Y  
45 (C4) UR-144 N/A C20H27NO; (1-Propyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
. . Y  
46 (C6)-CP 47,497 CP 47,497-C6-homolog C20H32O2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(2-methylheptan-2-
yl)phenol 
Y . Y  
47 (C9)-CP 47,497 CP 47,497-C9-homolog C23H38O2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(2-methyldecan-2-
yl)phenol 
Y . Y  
48 (CARBOXY) JWH-072 N/A C22H17NO3; 3-[3-(Naphthalene-1-carbonyl)-1H-indol-1-yl]propanoic 
acid 
. . Y  
49 (CHM) JWH-210 N/A C28H29NO; [1-(Cyclohexylmethyl)-1H-indol-3-yl](4-ethylnaphthalen-1-
yl)methanone 
. . Y  
50 (CHM) JWH-412 N/A C26H24FNO; [1-(Cyclohexylmethyl)-1H-indol-3-yl](4-fluoronaphthalen-
1-yl)methanone 
. . Y  
51 (CHM) UR-144 N/A C23H31NO; [1-(Cyclohexylmethyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
. . Y  
52 (CP) JWH-018 N/A C22H19NO; (1-Cyclopropyl-1H-indol-3-yl)(4a,8a-dihydronaphthalen-1-
yl)methanone 
. . Y  
53 (CPE) JWH-018 N/A C24H21NO; (1-Cyclopentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone . . Y  
54 (CPM) JWH-018 N/A C23H19NO; [1-(Cyclopropylmethyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
55 (CYCLOHEXYL) JWH-018 N/A C20H27NO; Cyclohexyl(1-pentyl-1H-indol-3-yl)methanone . . Y  
56 (DECALIN) JWH-018 N/A C24H33NO; (Decahydronaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
57 (DECYL) JWH-018 N/A C29H33NO; (1-Decyl-1H-indol-3-yl)(naphthalen-1-yl)methanone . . Y  
58 (DEGRADANT) A-796,260 N/A C22H30N2O2; (2E)-3,4,4-Trimethyl-1-{1-[2-(morpholin-4-yl)ethyl]-1H-
indol-3-yl}pent-2-en-1-on 
. . Y  
59 (HEXAHYDRO-2,5-METHANOPENTALEN-3A(1H)-YL){1-[(OXAN-
4-YL)METHYL]-1H-INDOL-3-YL}METHANONE 
N/A C24H29NO2;  (Hexahydro-2,5-methanopentalen-3a(1H)-yl){1-[(oxan-4-
yl)methyl]-1H-indol-3-yl}methanone 
. . Y  















. . Y  





. . Y  
66 (OCTYL) JWH-018 N/A C27H29NO; (Naphthalen-1-yl)(1-octyl-1H-indol-3-yl)methanone . . Y  
67 (ORIGINAL) SDB-005 n-phenyl SDB-006 C20H22N2O; 1-Pentyl-N-phenyl-1H-indole-3-carboxamide Y Y Y  
68 (PENTENYL) AM-694 N/A C20H18INO; (2-Iodophenyl)[1-(pent-4-en-1-yl)-1H-indol-3-
yl]methanone 
. . Y  
69 (PENTENYL) JWH-149 N/A C26H25NO; (4-Methylnaphthalen-1-yl)[2-methyl-1-(pent-4-en-1-yl)-1H-
indol-3-yl]methanone 
Y Y Y  
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70 (PIPET) AM-1220 N/A C26H26N2O; (Naphthalen-1-yl){1-[2-(piperidin-1-yl)ethyl]-1H-indol-3-
yl}methanone 
. . Y  
71 (R,R)-EPI-CP 47,497 N/A C21H34O2; 2-[(1R,3R)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
yl)phenol 
. . Y  
72 (S,S)-EPI-(C8)-CP 47,497 N/A C22H36O2; 2-[(1S,3S)-3-Hydroxycyclohexyl]-5-(2-methylnonan-2-
yl)phenol 
. . Y  
73 (S,S)-EPI-CP 47,497 N/A C21H34O2; 2-[(1S,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-
yl)phenol 
. . Y  
74 (THPM) JWH-018 N/A C25H23NO2; (Naphthalen-1-yl){1-[(oxan-4-yl)methyl]-1H-indol-3-
yl}methanone 
. . Y  
75 [1-(2-METHOXYETHYL)-1H-INDOL-3-YL](2,2,3,3-
TETRAMETHYLCYCLOPROPYL)METHANONE 
N/A C19H25NO2;  [1-(2-Methoxyethyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
. . Y  
76 [1-(5-FLUOROPENTYL)-6-NITRO-1H-INDOL-3-YL](2-
IODOPHENYL)METHANONE 
HONGFENG DENG PHD #7.15 C20H18FIN2O3; [1-(5-Fluoropentyl)-6-nitro-1H-indol-3-yl](2-
iodophenyl)methanone 




























. . Y  
82 {1-[(1-METHYLPIPERIDIN-2-YL)METHYL]-1H-INDOL-3-
YL}(OCTAHYDROQUINOLIN-1(2H)-YL)METHANONE 
N/A C25H35N3O;  {1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-
yl}(octahydroquinolin-1(2H)-yl)methanone 























































. . Y  















. . Y  
97 1-(1-NAPHTHYLMETHYLENE)INDENE N/A C20H14; 1-[(E)-1H-Inden-1-ylidenemethyl]naphthalene . . Y  
98 1-(2-NAPHTHYLMETHYL)INDENE N/A 1-(2-Naphthylmethyl)indene . . Y  
99 1-(2-NAPHTHYLMETHYLENE)INDENE N/A 1-(2-Naphthylmethylene)indene . . Y  
100 1-(5-FLUOROPENTYL)-3-(2-ETHYLBENZOYL)INDOLE AM-694 ethyl substituted for iodine C22H24FNO; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-
ethylphenyl)methanone; (2-Ethylphenyl)[1-(5-fluoropentyl)-1H-indol-3-
yl]methanone 













. . Y  
1’03 1-BENZYL-N-(QUINOLIN-8-YL)-1H-INDAZOLE-3-CARBOXAMIDE N/A C24H18N4O; 1-Benzyl-N-(quinolin-8-yl)-1H-indazole-3-carboxamide Y . .  










. . Y  
107 1-CYCLOHEXYLETHYL-3-(2-METHOXYPHENYLACETYL)INDOLE RCS-8 C25H29NO2; 1-[1-(2-cyclohexylethyl)indol-3-yl]-2-(2-
methoxyphenyl)ethanone 





. . Y  
109 1-PENTYL 3-(P-TOLYL) INDOLE N/A C21H23NO; (4-Methylphenyl)(1-pentyl-1H-indol-3-yl)methanone . . Y  
110 1-PENTYL 3-BENZOYL INDOLE N/A C20H21NO; (1-Pentyl-1H-indol-3-yl)(phenyl)methanone . . Y  
111 1-PENTYL-N-(QUINOLIN-8-YL)-1H-INDOLE-3-CARBOXAMIDE N/A C23H23N3O; 1-pentyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide Y . .  
112 1H-INDOL-3-YL-(1-NAPHTHYL)METHANE 3-(1-NAPHTHYLMETHANE)INDOLE C19H15N; 1H-Indol-3-yl-(1-naphthyl)methane . . Y  
113 1H-INDOL-3-YL-(2-NAPHTHYL)METHANE 3-(2-NAPHTHYLMETHANE)INDOLE 1H-Indol-3-yl-(2-naphthyl)methane . . Y  
114 2-[(1R,2R,5R)-5-HYDROXY-2-(HYDROXYMETHYL)CYCLOHEXYL]-
5-(2-METHYLOCTAN-2-YL)PHENOL 
US 4371720 #1-1 C22H36O3; 2-[(1R,2R,5R)-5-Hydroxy-2-(hydroxymethyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
115 2-[(1R,2S,5R)-5-HYDROXY-2-(2-HYDROXYETHYL)CYCLOHEXYL]-
5-(2-METHYLOCTAN-2-YL)PHENOL 
US 4371720 #1-2 C23H38O3;  2-[(1R,2S,5R)-5-Hydroxy-2-(2-hydroxyethyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
116 2-[5-HYDROXY-2-(3-HYDROXYPROPYL)PHENYL]-5-(2-
METHYLOCTAN-2-YL)BENZENE-1,3-DIOL 
US 2004/0087590 #25 C24H34O4; 6′-(3-Hydroxypropyl)-4-(2-methyloctan-2-yl)[1,1′-biphenyl]-
2,3′,6-triol 





. . Y  
118 2-AGE Noladin ether C23H40O3; 2-{[(5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraen-1-
yl]oxy}propane-1,3-diol 
. . Y  
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119 2-BROMOPHENYL 4-METHYL-3-(PIPERIDINE-1-
SULFONYL)BENZOATE 
N/A C19H20BrNO4S; 2-Bromophenyl 4-methyl-3-(piperidine-1-
sulfonyl)benzoate 
. . Y  
120 2-DESMETHYL WIN 55212-2 N/A C26H24N2O3; {(3R)-3-[(Morpholin-4-yl)methyl]-2,3-
dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl}(naphthalen-1-yl)methanone 
. . Y  
121 2-ETHOXY-N-[5-METHYL-3-(OXAN-4-YLMETHYL)-1,3-THIAZOL-
2-YLIDENE]BENZAMIDE 
US 2008/058335 #203 C19H24N2O3S; 2-Ethoxy-N-{5-methyl-3-[(oxan-4-yl)methyl]-1,3-thiazol-
2(3H)-ylidene}benzamide 
. . Y  
122 2-ETHYL-4,4-DIMETHYL-7-(2-METHYLOCTAN-2-YL)-2,4-
DIHYDRO[1]BENZOPYRANO[4,3-C]PYRAZOL-9-OL 
N/A C23H34N2O2;  2-Ethyl-4,4-dimethyl-7-(2-methyloctan-2-yl)-2,4-
dihydro[1]benzopyrano[4,3-c]pyrazol-9-ol 
. . Y  





Y . .  
124 2-FUB-007 N/A C27H20FNO; {1-[(2-Fluorophenyl)methyl]-2-methyl-1H-indol-3-
yl}(naphthalen-1-yl)methanone 
. . Y  
125 2-FUB-SDB-005 N/A C25H17FN2O2; Naphthalen-1-yl 1-[(2-fluorophenyl)methyl]-1H-
indazole-3-carboxylate 
. . Y  
126 2-ME-5F-PB-22 N/A C24H23FN2O2; Quinolin-8-yl 1-(5-fluoropentyl)-2-methyl-1H-indole-3-
carboxylate 
. . Y  
127 2-ME-MAM-2201 N/A C26H26FNO; [1-(5-Fluoropentyl)-2-methyl-1H-indol-3-yl](4-
methylnaphthalen-1-yl)methanone 
. . Y  
28 2-ME-XLR-11 N/A C22H30FNO; [1-(5-Fluoropentyl)-2-methyl-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 





. . Y  
130 2-METHYL-UR-12 N/A C27H39N3O3; 7-Methoxy-2-methyl-1-[2-(morpholin-4-yl)ethyl]-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-
carboxamide 





. . Y  






Y Y Y  
133 2'-CL-AM-694 N/A C20H19ClFNO; (2-Chlorophenyl)[1-(5-fluoropentyl)-1H-indol-3-
yl]methanone 




tolyl)methanone; AM-694 methyl 
substituted for iodine 
C21H22FNO; [1-(5-Fluoropentyl)-1H-indol-3-yl](2-
methylphenyl)methanone 
Y Y Y  
135 2'-MEO-AM-694 N/A C21H22FNO2; [1-(5-Fluoropentyl)-1H-indol-3-yl](2-
methoxyphenyl)methanone 
. . Y  
136 2'-METHOXY-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-OL N/A C22H30O2; 2′-Methoxy-4-(2-methyloctan-2-yl)[1,1′-biphenyl]-2-ol . . Y  
137 2',5'-DIMETHYL-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-
OL 
N/A C23H32O; 2′,5′-Dimethyl-4-(2-methyloctan-2-yl)[1,1′-biphenyl]-2-ol . . Y  
138 2',6'-DIMETHYL-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-
OL 
N/A C23H32O; 2′,6′-Dimethyl-4-(2-methyloctan-2-yl)[1,1′-biphenyl]-2-ol . . Y  
139 2F-AB-PINACA AB-PINACA N-(2-fluoropentyl) C18H25FN4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(2-
fluoropentyl)-1H-indazole-3-carboxamide 
Y Y Y  
140 2F-NNEI N/A C24H23FN2O; 1-(2-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-
carboxamide 
. . Y  
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. . Y  
143 3-(1-ADAMANTOYL)INDOLE N/A 3-(1-Adamantoyl)indole . . Y  
144 3-(1-NAPHTHOYL)INDOLE N/A 3-(1-Naphthoyl)indole . . Y  
145 3-(1-NAPHTHOYL)PYRROLE N/A 3-(1-Naphthoyl)pyrrole . . Y  
146 3-(2-ADAMANTOYL)INDOLE N/A 3-(2-Adamantoyl)indole . . Y  
147 3-(2-NAPHTHOYL)INDOLE N/A 3-(2-Naphthoyl)indole . . Y  
148 3-(2-NAPHTHOYL)PYRROLE 3-(2-NAPHTHOYL)PYRROLE 3-(2-Naphthoyl)pyrrole . . Y  
149 3-(2,2,3,3-TETRAMETHYLCYCLOPROPYLCARBONYL)INDOLE N/A 3-(2,2,3,3-Tetramethylcyclopropylcarbonyl)indole . . Y  
150 3-(4-HYDROXYMETHYLBENZOYL)-1-PENTYLINDOLE Tai High C21H23NO2; [4-(hydroxymethyl)phenyl]-(1-pentylindol-3-
yl)methanone 










Y . .  
153 3-(P-METHOXYBENZOYL)-N-METHYLINDOLE (4-methoxyphenyl)(1-methyl-1H-indol-3-
yl)methanone; 3-(p-methoxybenzoyl)-N-
methylindole; AC1MI47J; LS-91297 
C17H15NO2; (4-methoxyphenyl)-(1-methylindol-3-yl)methanone Y Y Y  
154 3-CAF N/A C24H15FN2O2; Naphthalen-2-yl 1-(2-fluorophenyl)-1H-indazole-3-
carboxylate 
. . Y  
155 3-CARBOXAMIDEINDAZOLE N/A 3-Carboxamideindazole . . Y  
156 3-CARBOXAMIDEINDOLE N/A 3-Carboxamideindole . . Y  
157 3-CL-PEA N/A C8H10ClN; 2-(3-Chlorophenyl)ethan-1-amine . . Y  





Y . .  
149 3-PHENYLACETYLINDOLE N/A C16H13NO; 1-(1H-Indol-3-yl)-2-phenylethanone . . Y  
160 3,5-AB-CHMFUPPYCA  AB-CHFUPYCA; AB-CHMFUPPYCA C22H29FN4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-
(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide 





. . Y  
162 3',5'-DICHLORO-4-(2-METHYL-2-OCTANYL)-2,6-BIPHENYLDIOL US 2004/0087590 #1 C21H26Cl2O2; 3′,5′-Dichloro-4-(2-methyloctan-2-yl)[1,1′-biphenyl]-2,6-
diol 
. . Y  
163 3',5'-DIMETHYL-4-(2-METHYLOCTAN-2-YL)[1,1'-BIPHENYL]-2-
OL 





. . Y  
165 3''-ME-JWH-073 JWH-018 isopentyl isomer; N-(3-
Methylbutyl)-3-(1-naphthoyl)-indole; 
JWH-018 N-(3-methylbutyl) isomer 
C24H23NO; [1-(3-Methylbutyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
Y . Y  





. . Y  
167 3F-AMB N/A C19H26FN3O3; Methyl (2S)-2-{[1-(3-fluoropentyl)-1H-indazole-3-
carbonyl]amino}-3-methylbutanoate 






Y . .  
169 4-(1-HEXYLCYCLOPENTYL)-3',5'-DIMETHYL[1,1'-BIPHENYL]-2-
OL 
N/A C25H34O; 4-(1-Hexylcyclopentyl)-3′,5′-dimethyl[1,1′-biphenyl]-2-ol . . Y  
170 4-(1-HEXYLCYCLOPROPYL)-3',5'-DIMETHYL[1,1'-BIPHENYL]-2-
OL 





. . Y  





. . Y  
174 4-HO-UR-144 UR-144 N(4-HYDROXYPENTYL) C21H29NO2; 1-(4-Hydroxypentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
. . Y  
175 4-HTMPIPO N/A C21H31NO2; 4-hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-indol-3-yl)-1-
pentanone 










. . Y  
178 4-OH-ADB-CHMINACA N/A C21H30N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-
hydroxycyclohexyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
179 4-OH-TERT-LEUCINE-ADB-CHMINACA N/A C21H29N3O4; (2S)-2-({1-[(4-Hydroxycyclohexyl)methyl]-1H-indazole-3-
carbonyl}amino)-3,3-dimethylbutanoic acid; N-{1-[(4-
Hydroxycyclohexyl)methyl]-1H-indazole-3-carbonyl}-3-methyl-L-valine 

















. . Y  
183 4'-ET-JWH-200 N/A C27H28N2O2; (4-Ethylnaphthalen-1-yl){1-[2-(morpholin-4-yl)ethyl]-1H-
indol-3-yl}methanone 
. . Y  
184 4CN-ADB N/A C20H26N4O3; Methyl (2S)-2-{[1-(4-cyanobutyl)-1H-indazole-3-
carbonyl]amino}-3,3-dimethylbutanoate; Methyl N-[1-(4-cyanobutyl)-
1H-indazole-3-carbonyl]-3-methyl-L-valinate 
. . Y  
185 4F-AB-PINACA N/A C18H25FN4O2; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluoropentyl)-1H-indazole-3-carboxamide 
Y . .  
186 4F-ADB 4F-MDMB-BINACA C19H26FN3O3; Methyl (2S)-2-{[1-(4-fluorobutyl)-1H-indazole-3-
carbonyl]amino}-3,3-dimethylbutanoate 
Y Y Y  
187 4F-AKB48 N/A C22H28FN3O; N-(Adamantan-1-yl)-1-(4-fluorobutyl)-1H-indazole-3-
carboxamide 
. . Y  
188 4F-AMB N/A C19H26FN3O3; methyl (1-(4-fluoropentyl)-1H-indazole-3-carbonyl)-L-
valinate 
Y . .  
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189 4F-NNEI 4F-MN-24 C24H23FN2O; 1-(4-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-
carboxamide 
Y . Y  
190 4F-PB-22 N/A C22H19FN2O2; Quinolin-8-yl 1-(4-fluorobutyl)-1H-indole-3-carboxylate . . Y  
191 4F3-JWH-073 TFB-073 C23H18F3NO; (Naphthalen-1-yl)[1-(4,4,4-trifluorobutyl)-1H-indol-3-
yl]methanone 
. . Y  
192 4HO-AM-2201 AM2201 N-(4-hydroxypentyl) metabolite C24H22FNO; [1-(5-Fluoro-4-hydroxypentyl)-1H-indol-3-yl](naphthalen-
1-yl)methanone 
. . Y  
193 4Q3C 4-Quinolone-3-Carboxamide C26H34N2O3; N-(Adamantan-1-yl)-8-methoxy-4-oxo-1-pentyl-1,4-
dihydroquinoline-3-carboxamide 
. . Y  
194 5-(ADAMANTAN-1-YL)-2-[(1R,2R,5R)-5-(HYDROXYMETHYL)-2-
(PROP-1-EN-2-YL)CYCLOHEXYL]BENZENE-1,3-DIOL 
N/A C26H36O3;  5-(Adamantan-1-yl)-2-[(1R,2R,5R)-5-(hydroxymethyl)-2-
(prop-1-en-2-yl)cyclohexyl]benzene-1,3-diol 
. . Y  
195 5-BR-THJ-018 5-bromopentyl JWH 018 indazole analog C23H21BrN2O; [1-(5-Bromopentyl)-1H-indazol-3-yl](naphthalen-1-
yl)methanone 








. . Y  
197 5-FLUOROPENTYL-3-PYRIDINOYLINDOLE N/A C19H19FN2O; [2-(5-fluoropentyl)-1H-indol-3-yl]-pyridin-2-ylmethanone Y Y Y  
198 5,3-AB-CHFUPYCA AB-CHFUPYCA; AB-CHMFUPPYCA C22H29FN4O2; (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 






. . Y  





Y . .  
201 5BR-JWH-018 N/A C24H22BrNO; [1-(5-Bromopentyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
Y Y Y  
202 5BR-JWH-122 N/A C25H24BrNO; [1-(5-Bromopentyl)-1H-indol-3-yl](4-methylnaphthalen-
1-yl)methanone 
. . Y  




Y . Y  
204 5C-AKB48 5Cl-AKB48; 5C-APINACA C23H30ClN3O; N-(Adamantan-1-yl)-1-(5-chloropentyl)-1H-indazole-3-
carboxamide 
Y Y Y  
205 5CL-AB-PINACA N/A C18H25ClN4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-
chloropentyl)-1H-indazole-3-carboxamide 
Y Y Y  
206 5CL-AM-694 N/A C20H19ClINO; [1-(5-Chloropentyl)-1H-indol-3-yl](2-
iodophenyl)methanone 
Y Y Y  
207 5CL-CUMYL-PEGACLONE N/A C25H27ClN2O; 5-(5-chloropentyl)-2-(2-phenylpropan-2-yl)-2,5-dihydro-
1H-pyrido[4,3-b]indol-1-one 
Y . .  
208 5CL-JWH-018 N/A C24H22ClNO; [1-(5-Chloropentyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
Y Y Y  
209 5CL-JWH-122 N/A C25H24ClNO; [1-(5-Chloropentyl)-1H-indol-3-yl](4-methylnaphthalen-
1-yl)methanone 
Y Y Y  
210 5CL-MDMB-PINACA Cl-ADB C20H28ClN3O3; Methyl (2S)-2-{[1-(5-chloropentyl)-1H-indazole-3-
carbonyl]amino}-3,3-dimethylbutanoate 
Y Y Y  
211 5CL-NNE1 5Cl-NNEI C24H23ClN2O; 1-(5-Chloropentyl)-N-(naphthalen-1-yl)-1H-indole-3-
carboxamide 
Y . Y  
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Y Y Y  
213 5CL-UR-144 UR-144 N-(5-chloropentyl) derivative C21H28ClNO;  [1-(5-Chloropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
214 5CN-UR-144 N/A C21H26N2O; 5-[3-(2,2,3,3-Tetramethylcyclopropane-1-carbonyl)-1H-
indol-1-yl]pentanenitrile 
. . Y  
215 5F-3,5-AB-PFUPPYCA N/A C20H26F2N4O2; N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide 
Y Y Y  
216 5F-3,5-ADB-PFUPPYCA N/A C21H28F2N4O2; N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide 
. . Y  
217 5F-AB-2PINACA N/A C18H25FN4O2: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-2-(5-
fluoropentyl)-2H-indazole-3-carboxamide 
. . Y  
218 5F-AB-FUPPYCA AZ-037 C20H26F2N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-
fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide 
Y Y Y  
219 5F-AB-P7AICA  N/A C18H25FN4O2; N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoro- 
pentyl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide 
. Y .  
220 5F-AB-PICA 5F-ABICA; 5F-AMBICA C19H26FN3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(5-
fluoropentyl)-1H-indole-3-carboxamide 
Y Y Y  
221 5F-AB-PINACA N/A C18H25FN4O2; N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-(5-
fluoropentyl)indazole-3-carboxamide 
Y Y Y  
222 5F-ADB-PICA 5F-ADBICA C20H28FN3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-
fluoropentyl)-1H-indole-3-carboxamide 
Y Y Y  
223 5F-ADB-PINACA N/A C19H27FN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(5-
fluoropentyl)-1H-indazole-3-carboxamide 
Y Y Y  
224 5F-AEB N/A C20H28FN3O3; Ethyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-
carbonyl]amino}-3-methylbutanoate 
Y . Y  
225 5F-AKB-48-7N 5F-7-APAICA; 5F-A-P7AICA C23H30FN3O; N-(Adamantan-1-yl)-1-(5-fluoropentyl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxamide 
. Y Y  
226 5F-AKB-57 N/A C23H29FN2O2; Adamantan-1-yl 1-(5-fluoropentyl)-1H-indazole-3-
carboxylate 
Y Y Y  




Y Y Y  
228 5F-AMPPPCA D-DOFC; (+)-5F-Dioxolane-C; (+)-FDOC C26H34FN3O; N-(Adamantan-1-yl)-1-(5-fluoropentyl)-4-methyl-5-
phenyl-1H-pyrazole-3-carboxamide 
. . Y  
229 5F-APP-PICA PX-1; SRF-30 C23H26FN3O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(5-
fluoropentyl)-1H-indole-3-carboxamide 
Y Y Y  
230 5F-APP-PINACA PPA(N)-2201; FU-PX; PX-2 C22H25FN4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(5-
fluoropentyl)-1H-indazole-3-carboxamide 
Y Y Y  
231 5F-CHP-PINACA SGT-74 C20H28FN3O; N-Cycloheptyl-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide 
. . Y  
232 5F-CPM-PINACA N/A C19H26FN3O; N-(Cyclopentylmethyl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide 
. . Y  
233 5F-CUMYL-PEGACLONE N/A C25H27FN2O; 5-(5-Fluoropentyl)-2-(2-phenylpropan-2-yl)-2,5-dihydro-
1H-pyrido[4,3-b]indol-1-one 
Y Y Y  
234 5F-CYP-PINACA N/A C17H22FN3O; N-(Cyclopropylmethyl)-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide 
. . Y  
235 5F-CYPPICA N/A C18H23FN2O; N-(Cyclopropylmethyl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide 
. . Y  
236 5F-EDMB-PINACA N/A C21H30FN3O3; ethyl (S)-2-(1-(5-fluoropentyl)-1H-indazole-3-
carboxamido)-3,3-dimethylbutanoate 
Y Y Y  
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237 5F-EMB-PICA N/A C21H29FN2O3; Ethyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-
carbonyl]amino}-3-methylbutanoate; Ethyl N-[1-(5-fluoropentyl)-1H-
indole-3-carbonyl]-L-valinate 
. . Y  
238 5F-EMB-PINACA N/A C20H28FN3O3; ethyl (1-(5-fluoropentyl)-1H-indazole-3-carbonyl)-L-
valinate 
Y Y Y  
239 5F-IPBN-P7AICA N/A C23H28FN3O; 1-(5-Fluoropentyl)-N-(2-methyl-1-phenylpropyl)-1H-
pyrrolo[2,3-b]pyridine-3-carboxamide 
. . Y  
240 5F-MDA-19-AD N/A C24H30FN3O2; N′-[1-(5-Fluoropentyl)-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]adamantane-1-carbohydrazide 
. . Y  
241 5F-MDA-19-TMCP N/A C21H28FN3O2; N′-[1-(5-Fluoropentyl)-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]-2,2,3,3-tetramethylcyclopropane-1-carbohydrazide 
. . Y  
242 5F-MDMB-2201 N/A C22H29FN4O2; methyl 2-(1-(5-fluoropentyl)-1h-indol-3-carboxamido)-
3,3-dimethylbutanoate 
. . Y  
243 5F-MDMB-P4AICA N/A C20H28FN3O3; methyl 2-(1-(5-fluoropentyl)-1H-pyrrolo[3,2-b]pyridine-
3-carboxamido)-3,3-dimethylbutanoate 
Y . Y  




Y Y Y  
245 5F-MDMB-PICA N/A C21H29FN2O3; N-[[1-(5-fluoropentyl)-1H-indol-3-yl]carbonyl]-3-
methyl-L-valine, methyl ester 
Y Y Y  






Y Y Y  
247 5F-MMB-PICA I-AMB; 5F-AMB-PICA; MMB-2201 C20H27FN2O3; Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-
carbonyl]amino}-3-methylbutanoate 
Y Y Y  
248 5F-MMB-PINACA 5F-AMB-PINACA; 5F-AMB C19H26FN3O3; Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-
carbonyl]amino}-3-methylbutanoate 
Y Y Y  
249 5F-MN-18 N/A C23H22FN3O; N-1-naphtalenyl-1-(5-fluoropentyl)-1H-indazole-3-
carboxamide 
Y Y Y  
250 5F-MPP-PICA MPHP-2201 C24H27FN2O3; Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indole-3-
carbonyl]amino}-3-phenylpropanoate; Methyl N-[1-(5-fluoropentyl)-
1H-indole-3-carbonyl]-L-phenylalaninate 
Y Y Y  
251 5F-MPP-PINACA N/A C23H26FN3O3; Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-
carbonyl]amino}-3-phenylpropanoate 
. . Y  
252 5F-MSB-PINACA N/A C20H28FN3O3; Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-
carbonyl]amino}-3-methylpentanoate 
. . Y  
253 5F-NNE1 5F-MN-24; 5F-NNEI C24H23FN2O; 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-
carboxamide 
Y . Y  




Y Y Y  
255 5F-NPB-22-7N 7N-5F-PB-22 C22H20FN3O2; Quinolin-8-yl 1-(5-fluoropentyl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxylate 
. . Y  
256 5F-PB-22 5-INPB-22 C23H21FN2O2; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl 
ester 
Y Y Y  
257 5F-PB-22 AMIDE N/A C23H22FN3O; 1-(5-Fluoropentyl)-N-(quinolin-8-yl)-1H-indole-3-
carboxamide 
. . Y  
258 5F-PB-22 INDAZOLE ANALOGUE QCBL(N)2201; 5F NPB-22; 5F-inpb-22 C22H20FN3O2; Quinolin-8-yl 1-(5-fluoropentyl)-1H-indazole-3-
carboxylate 
Y Y Y  
259 5F-PB-22-3Q N/A C23H21FN2O2; Quinolin-3-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
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260 5F-PB-22-4IQ N/A C23H21FN2O2; Isoquinolin-4-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
261 5F-PB-22-4Q N/A C23H21FN2O2; Quinolin-4-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
262 5F-PB-22-5IQ N/A C23H21FN2O2; Isoquinolin-5-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
263 5F-PB-22-5Q N/A C23H21FN2O2; Quinolin-5-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
264 5F-PB-22-6IQ N/A C23H21FN2O2; Isoquinolin-6-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
265 5F-PB-22-6Q N/A C23H21FN2O2; Quinolin-6-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
266 5F-PB-22-7IQ N/A C23H21FN2O2; Isoquinolin-7-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
267 5F-PB-22-7Q N/A C23H21FN2O2; Quinolin-7-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
268 5F-PB-22-8IQ N/A C23H21FN2O2; Isoquinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
. . Y  
269 5F-PC6N N/A C23H22FN3O; 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[2,3-
c]pyridine-3-carboxamide 
. . Y  
270 5F-PCN 5-F-MN-21; C23H22FN3O; 1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-
c]pyridine-3-carboxamide 
Y . Y  
271 5F-PNI-D N/A C20H18Cl2FNO; (2,3-Dichlorophenyl)[1-(5-fluoropentyl)-1H-indol-3-
yl]methanone 
. . Y  
272 5F-PY-PICA 5-fluoro PY-PICA C18H23FN2O; (1-(5-fluoropentyl)-1H-indol-3-yl)(pyrrolidin-1-
yl)methanone 
Y Y Y  
273 5F-PY-PINACA N/A C17H22FN3O; [1-(5-Fluoropentyl)-1H-indazol-3-yl](pyrrolidin-1-
yl)methanone 
Y Y Y  
274 5F-SDB-005 CBL(N)2201 C23H21FN2O2; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-
carboxylate 
Y Y Y  
275 5F-SDB-006 N/A C21H23FN2O; N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide Y Y Y  
276 5F-THFM-PINACA N/A C18H24FN3O2; 1-(5-Fluoropentyl)-N-[(oxolan-2-yl)methyl]-1H-
indazole-3-carboxamide 
. . Y  
277 5F-THJ N/A C22H21FN4O; 1-(5-Fluoropentyl)-N-(quinolin-8-yl)-1H-indazole-3-
carboxamide 
Y . Y  
278 5I-JWH-122 N/A C25H24INO; [1-(5-Iodopentyl)-1H-indol-3-yl](4-methylnaphthalen-1-
yl)methanone 
. . Y  

























. . Y  
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283 6-IODOPRAVADOLINE AM-630 C23H25IN2O3; {6-Iodo-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-
3-yl}(4-methoxyphenyl)methanone 
. . Y  
284 6-ME-JWH-200 N/A C26H26N2O2; {6-Methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-
yl}(naphthalen-1-yl)methanone 
. . Y  
285 6-MEO-JWH-018 N/A C25H25NO2; (6-Methoxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 







. . Y  
287 6,6,9-TRIMETHYL-3-PENTYL-7,8,9,10-TETRAHYDRO-6H-
DIBENZO[B,D]PYRAN-1-AMINE 
N/A C21H31NO;  6,6,9-Trimethyl-3-pentyl-7,8,9,10-tetrahydro-6H-
dibenzo[b,d]pyran-1-amine 
. . Y  
288 6F-AB-HINACA N/A C19H27FN4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(6-
fluorohexyl)-1H-indazole-3-carboxamide 
. . Y  
289 6F-JWH-019 N/A C25H24FNO; [1-(6-Fluorohexyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 












. . Y  
292 7-METHOXY-1-[2-(MORPHOLIN-4-YL)ETHYL]-N-[(2R)-1-
PHENYLPROPAN-2-YL]-1H-INDOLE-3-CARBOXAMIDE 
N/A C25H31N3O3;  7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[(2R)-1-
phenylpropan-2-yl]-1H-indole-3-carboxamide 






. . Y  
294 7'-MEO-NABUTIE 7'-methoxy NABUTIE C25H25NO2; 1-(1-Butyl-7-methoxy-1H-indol-3-yl)-2-(naphthalen-1-
yl)ethan-1-one 
. . Y  
295 7N-AB-FUBINACA N/A C20H21FN4O2: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-
fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridine-3-carboxamide 
. . Y  
296 7N-THJ-2201 N/A C23H21FN2O; [1-(5-Fluoropentyl)-1H-pyrrolo[2,3-b]pyridin-3-
yl](naphthalen-1-yl)methanone 










. . Y  
299 9B-OH-9-NHHC 9-Nor-9β-hydroxyhexahydrocannabinol C20H30O3; (6aR,9R,10aR)-6,6-Dimethyl-3-pentyl-6a,7,8,9,10,10a-
hexahydro-6H-dibenzo[b,d]pyran-1,9-diol 
. . Y  
300 A-40174 N/A C26H37NO2; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-2-(prop-2-yn-1-yl)-
1,3,4,5-tetrahydro-2H-[1]benzopyrano[4,3-c]pyridin-10-ol 
. . Y  
301 A-41988 BW29Y C28H32FNO2; 8-[5-(4-Fluorophenyl)pentan-2-yl]-5,5-dimethyl-2-(prop-
2-yn-1-yl)-1,3,4,5-tetrahydro-2H-[1]benzopyrano[4,3-c]pyridin-10-ol 
. . Y  
302 A-796,260 N/A C22H30N2O2; [1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
303 A-796,260 OPEN CHAIN ISOMER A-796,260 isomer C22H30N2O2; (E)-3,4,4-trimethyl-1-(1-(2-morpholinoethyl)-1H-indol-3-
yl)pent-2-en-1-one 
Y Y Y  
304 A-834,735 N/A C22H29NO2; {1-[(Oxan-4-yl)methyl]-1H-indol-3-yl}(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
305 A-836,339 N/A C16H26N2O2S; N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-
ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide 
Y Y Y  
306 AB-002 N/A C25H33NO; 2-(Adamantan-1-yl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one . . Y  
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307 AB-005 N/A C23H32N2O; {1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
308 AB-034 N/A C23H32N2O; [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-
(2,2,3,3-tetramethylcyclopropyl)methanone 
. . Y  
309 AB-2CHMINACA ZINC299817316 C20H28N4O2: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-2-
(cyclohexylmethyl)-2H-indazole-3-carboxamide 
Y . Y  




. . Y  
311 AB-2PINACA N/A C18H26N4O2: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-2-pentyl-2H-
indazole-3-carboxamide 
. . Y  
312 AB-BICA N/A C21H23N3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-benzyl-
1H-indole-3-carboxami 
. . Y  
313 AB-CHMICA N/A C21H29N3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-
(cyclohexylmethyl)-1H-indole-3-carboxamide 
Y . Y  
314 AB-CHMINACA N/A C20H28N4O2; N-(1-AMINO-3-METHYL-1-OXOBUTAN-2-YL)-1-
(CYCLOHEXYLMETHYL)-1H-INDAZOLE-3-CARBOXAMIDE 
Y Y Y  
315 AB-FUBICA N/A C21H22FN3O2: N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-
fluorophenyl)methyl]-1H-indole-3-carboxamide 
. . Y  
316 AB-FUBINACA Ab-fubi; Ab-fubi;AB-FUBINACA C20H21FN4O2; N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 
Y Y Y  
317 AB-FUBINACA 2-FLUOROBENZYL ISOMER N/A C20H21FN4O2;  N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(2-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 
Y Y Y  
318 AB-FUBINACA 3-FLUOROBENZYL ISOMER N/A C20H21FN4O2; (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(3-
fluorobenzyl)-1H-indazole-3-carboxamide 
Y . .  
319 AB-FUBINACA-COOH N/A C20H20FN3O3; (2S)-2-({1-[(4-Fluorophenyl)methyl]-1H-indazole-3-
carbonyl}amino)-3-methylbutanoic acid 
. . Y  
320 AB-HINACA HEXENYL N/A C19H26N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(hex-5-en-
1-yl)-1H-indazole-3-carboxamide 
. . Y  
321 AB-PICA N/A C19H27N3O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-pentyl-1H-
indole-3-carboxamide 
Y . Y  
322 AB-PINACA N/A C18H26N4O2; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide 
Y Y Y  
323 AB-PINACA PENTENYL N/A C18H24N4O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(pent-4-
en-1-yl)-1H-indazole-3-carboxamide 
. . Y  
324 AB-PINACA-COOH N-(1-Pentyl-1H-indazole-3-carbonyl)-L-va C18H25N3O3; (2S)-3-Methyl-2-[(1-pentyl-1H-indazole-3-
carbonyl)amino]butanoic acid 
. . Y  
325 ACPA Arachidonylcyclopropylamide C23H37NO; (5Z,8Z,11Z,14Z)-N-Cyclopropylicosa-5,8,11,14-
tetraenamide 
. . Y  
326 AD-CHM N/A C26H33NO; (Adamantan-1-yl)[1-(cyclohexylmethyl)-1H-indol-3-
yl]methanone 
. . Y  
327 AD-ME N/A C25H32N2O2; (Adamantan-1-yl){1-[2-(morpholin-4-yl)ethyl]-1H-indol-
3-yl}methanone 
. . Y  
328 AD-THPM N/A C25H31NO2; (Adamantan-1-yl){1-[(oxan-4-yl)methyl]-1H-indol-3-
yl}methanone 
. . Y  
329 ADB-BICA N/A C22H25N3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
benzyl-1H-indole-3-carboxamide 
. . Y  
330 ADB-BINACA N/A C21H24N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
benzyl-1H-indazole-3-carboxamide 
. . Y  
331 ADB-CHMICA N/A C22H31N3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
(cyclohexylmethyl)-1H-indole-3-carboxamide 
Y Y Y  
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332 ADB-CHMINACA MAB-CHMINACA C21H30N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
(cyclohexylmethyl)indazole-3-carboxamide 
Y Y Y  
333 ADB-FUBICA N/A C22H24FN3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-
fluorophenyl)methyl]-1H-indole-3-carboxamide 
Y . Y  
334 ADB-FUBINACA N/A C21H23FN4O2; 2-[2-[1-[(4-fluorophenyl)methyl]indazol-3-yl]-2-oxo-
ethyl]-3;3-dimethyl-butanamide 
Y Y Y  
335 ADB-PINACA N/A C19H28N4O2; N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-
indazole-3-carboxamide 
Y Y Y  
336 ADB-PINACA (ISOMER 1)  N/A C19H28N4O2; N-[(2S)-1-Amino-2,3-dimethyl-1-oxobutan-2-yl]-1-
pentyl-1H-indazole-3-carboxamide 
. . Y  
337 ADB-PINACA (ISOMER 2)  N/A C19H28N4O2; N-[(2S,3S)-1-Amino-3-methyl-1-oxopentan-2-yl]-1-
pentyl-1H-indazole-3-carboxamide 
. . Y  
338 ADB-PINACA (ISOMER 3)  N/A C19H28N4O2; N-[(2S)-1-Amino-1-oxohexan-2-yl]-1-pentyl-1H-indazole-
3-carboxamide 
. . Y  
339 ADBICA 1445583-48-1 C20H29N3O2 N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indole-3-carboxamide 
Y Y Y  
340 ADSB-FUB-187 N/A C26H31ClFN5O4S; 7-Chloro-N-[(2S)-1-({2-
[(cyclopropanesulfonyl)amino]ethyl}amino)-3,3-dimethyl-1-oxobutan-
2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
Y . Y  
341 AFUBINACA FUB-APINACA; FUB-AKB48 C25H26FN3O N-(Adamantan-1-yl)-1-[(4-fluorophenyl)methyl]-1H-
indazole-3-carboxamide 
Y Y Y  
342 AKB-57 N/A C23H30N2O2; adamantan-1-yl 1-pentyl-1H-indazole-3-carboxylate Y Y Y  
343 AKB-N1 N/A C25H34N4O; N-(Adamantan-1-yl)-1-[2-(piperidin-1-yl)ethyl]-1H-
indazole-3-carboxamide 
. . Y  
344 ALICB-122 N/A C25H32N2O2; N-(Adamantan-1-yl)-4-oxo-1-pentyl-1,4-
dihydroquinoline-3-carboxamide 
. . Y  
345 AM-087 N/A C23H33BrO2: (6aR,10aR)-3-(6-Bromo-2-methylhexan-2-yl)-6,6,9-
trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
346 AM-1116 N/A C24H41NO2; (2R,5Z,8Z,11Z,14Z)-N-[(2R)-1-Hydroxypropan-2-yl]-2-
methylicosa-5,8,11,14-tetraenamide 
. . Y  
347 AM-11542 N/A C25H37BrO2; (6aR,10aR)-3-(8-Bromo-2-methyloctan-2-yl)-6,6,9-
trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
348 AM-1172 N/A C27H39NO2; 4-Hydroxy-N-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-
yl]benzamide 
Y . Y  
349 AM-1218 N/A C26H25N3O3; {1-[(1-Methylpiperidin-2-yl)methyl]-6-nitro-1H-indol-3-
yl}(naphthalen-1-yl)methanone 
. . Y  
350 AM-1220 N/A C26H26N2O; (R)-(1-((1-methylpiperidin-2-yl)methyl)-1H-indol-3-
yl)(naphthalen-1-yl)methanone 
Y Y Y  
351 AM-1221 N/A C27H27N3O3; {2-Methyl-1-[(1-methylpiperidin-2-yl)methyl]-6-nitro-1H-
indol-3-yl}(naphthalen-1-yl)methanone 
. . Y  
352 AM-1230 N/A C24H21FINO; [1-(5-Fluoropentyl)-6-iodo-1H-indol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
353 AM-1235 N/A C24H21FN2O3; [1-(5-Fluoropentyl)-6-nitro-1H-indol-3-yl](naphthalen-
1-yl)methanone 
. . Y  
354 AM-1241 N/A C22H22IN3O3; (2-Iodo-5-nitrophenyl){1-[(1-methylpiperidin-2-
yl)methyl]-1H-indol-3-yl}methanone 
Y . Y  
355 AM-1248 N/A C26H34N2O; 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-
oyl)indole 
Y Y Y  
356 AM-1248 AZEPANE ISOMER N/A C26H34N2O; adamantan-1-yl(1-(1-methylazepan-3-yl)-1H-indol-3-
yl)methanone 
Y Y Y  
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357 AM-1253 N/A C32H28N2O; {1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(pyren-
1-yl)methanone 
. . Y  
358 AM-1256 N/A C27H30N2O; [4-(Dimethylamino)naphthalen-1-yl](2-methyl-1-pentyl-
1H-indol-3-yl)methanone 
. . Y  
359 AM-1288 N/A C23H20INO; [1-(4-Iodobutyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
360 AM-1292 N/A C22H18INO; [1-(4-Iodobutyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
361 AM-1295 N/A C23H20FNO; [1-(4-Fluorobutyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
362 AM-1299 N/A C26H25N3O3; {1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(4-
nitronaphthalen-1-yl)methanone 
. . Y  
363 AM-1714 N/A C22H26O4; 1,9-Dihydroxy-3-(2-methyloctan-2-yl)-6H-
dibenzo[b,d]pyran-6-one 
. . Y  
364 AM-2201 N/A C24H22FNO; 1-[(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-
yl)methanone 
Y Y Y  
365 AM-2201 N-(4-FLUOROPENTYL) N/A C24H22FNO; (1-(4-fluoropentyl)-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
Y . .  




Y . Y  
367 AM-2203 N/A C24H22INO; [1-(5-Iodopentyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
368 AM-2210 N/A C23H19IN2O3; [1-(4-Iodobutyl)-1H-indol-3-yl](4-nitronaphthalen-1-
yl)methanone 
. . Y  
369 AM-2225 N/A C21H21FINO; [1-(5-Fluoropentyl)-2-methyl-1H-indol-3-yl](2-
iodophenyl)methanone 
. . Y  
370 AM-2231 N/A C24H19N3O3; 5-[3-(Naphthalene-1-carbonyl)-6-nitro-1H-indol-1-
yl]pentanenitrile 
. . Y  
371 AM-2232 N/A C24H20N2O; 5-[3-(Naphthalene-1-carbonyl)-1H-indol-1-
yl]pentanenitrile 
Y Y Y  
372 AM-2233 N/A C22H23IN2O; (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-
indol-3-yl]-methanone 
Y Y Y  




. . Y  
374 AM-2389 N/A C25H38O3; (6aR,9R,10aR)-3-(1-Hexylcyclobutyl)-6,6-dimethyl-
6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1,9-diol 
. . Y  
375 AM-251 N/A C22H21Cl2IN4O; 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl- N-
(1-piperidyl)pyrazole-3-carboxamide 
. . Y  
376 AM-281 N/A C21H19Cl2IN4O2; 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-
(morpholin-4-yl)-1H-pyrazole-3-carboxamide 
. . Y  
377 AM-4030 N/A C27H42O4; (6S,6aR,9R,10aR)-9-(Hydroxymethyl)-6-[(1E)-3-
hydroxyprop-1-en-1-yl]-6-methyl-3-(2-methyloctan-2-yl)-
6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
378 AM-404 N-Arachidonoylaminophenol C26H37NO2; (5Z,8Z,11Z,14Z)- N-(4-Hydroxyphenyl)icosa- 5,8,11,14-
tetraenamide 
. . Y  
379 AM-4054 N/A C26H36O3; (6aR,10aR)-3-(Adamantan-1-yl)-9-(hydroxymethyl)-6,6-
dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
380 AM-4056 HU-243 C25H40O3; (6aR,9R,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-
methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-
ol 
. . Y  
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381 AM-407 N/A C26H38O2; (6aR,10aR)-6,6,9-Trimethyl-3-[(1s,4R)-1-methyl-4-
propylcyclohexyl]-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
382 AM-411 N/A C26H34O2; (6aR,10aR)-3-(Adamantan-1-yl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
383 AM-6527 NNE1; NNEI; MN-24; JWH-018 
carboxamide derivative 
C24H24N2O; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide Y Y Y  
384 AM-6545 N/A C26H23Cl2N5O3S; 5-[4-(4-Cyanobut-1-yn-1-yl)phenyl]-1-(2,4-
dichlorophenyl)-N-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-methyl-1H-
pyrazole-3-carboxamide 
. . Y  
385 AM-664 N/A C23H24IN3O3; (2-Iodophenyl){2-methyl-1-[(1-methylpiperidin-2-
yl)methyl]-6-nitro-1H-indol-3-yl}methanone 
. . Y  
386 AM-669 N/A C21H22INO; (2-Iodophenyl)(2-methyl-1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
387 AM-679 AM XIAO; AM-694-F C20H20INO; (2-Iodophenyl)(1-pentyl-1H-indol-3-yl)methanone Y Y Y  
388 AM-682 N/A C22H24INO; (1-Hexyl-2-methyl-1H-indol-3-yl)(2-
iodophenyl)methanone 
. . Y  
389 AM-683 N/A C20H20INO; (1-Butyl-2-methyl-1H-indol-3-yl)(2-iodophenyl)methanone . . Y  
390 AM-694 N/A C20H19FINO; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-
iodophenyl)methanone 
Y Y Y  
391 AM-694 INDAZOLE ANALOGUE N/A C19H18FIN2O; [1-(5-Fluoropentyl)-1H-indazol-3-yl](2-
iodophenyl)methanone 
. . Y  
392 AM-729 N/A C27H36O2; (6aR,10aR)-3-[(Adamantan-1-yl)methyl]-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
393 AM-732 N/A C26H36O2; (6aR,10aR)-6,6,9-Trimethyl-3-(1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl)-6a,7,10,10a-tetrahydro-6H-
dibenzo[b,d]pyran-1-ol 
. . Y  
394 AM-852 N/A C26H37NO2; (5Z,8Z,11Z,14Z)-N-(2-Hydroxyphenyl)icosa-5,8,11,14-
tetraenamide 
. . Y  
395 AM-855 N/A C26H38O2; (4aR,12bR)-8-Hexyl-2,5,5-trimethyl-1,4a,5,8,9,10,11,12b-
octahydro-4H-benzo[d]naphtho[2,3-b]pyran-12-ol 
. . Y  
396 AM-881 ACEA C22H36ClNO; (5Z,8Z,11Z,14Z)-N-(2-Chloroethyl)icosa-5,8,11,14-
tetraenamide 
. . Y  
397 AM-883 N/A C23H37NO; (5Z,8Z,11Z,14Z)-N-(Prop-2-en-1-yl)icosa-5,8,11,14-
tetraenamide 
. . Y  
398 AM-905 N/A C23H34O3; (6aR,9R,10aR)-3-[(1E)-Hept-1-en-1-yl]-9-(hydroxymethyl)-
6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
399 AM-906 N/A C23H34O3; (6aR,9R,10aR)-3-[(1Z)-Hept-1-en-1-yl]-9-(hydroxymethyl)-
6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
400 AM-919 N/A C27H44O4; (6S,6aR,9R,10aR)-9-(Hydroxymethyl)-6-(3-hydroxypropyl)-
6-methyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-
dibenzo[b,d]pyran-1-ol 
. . Y  
401 AM-938 N/A C27H40O4; (6R,6aR,9R,10aR)-9-(Hydroxymethyl)-6-(3-hydroxyprop-1-
yn-1-yl)-6-methyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-
6H-dibenzo[b,d]pyran-1-ol 
. . Y  
402 AM-9405 GAT379 C24H32N2O2 · BrH; (2-(2,6-dihydroxy-4-(2-methyloctan-2-yl)phenyl)-
1,3-dimethyl-1H-benzo[d]imidazol-3-ium bromide) 
. . Y  
403 AMB N/A C19H27N3O3; methyl (1-pentyl-1H-indazole-3-carbonyl)-L-valinate Y . Y  
404 AMB-CHMINACA MA-CHMINACA; MMB-CHMINACA  C21H29N3O3; (2S)-methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-
ylcarbonylamino)-3,3-dimethylbutanoate 
Y Y Y  
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405 AMB-FUBICA N/A C22H25FN2O3; N-[[1-[(4-fluorophenyl)methyl]-1H-indol-3-yl]carbonyl]-
L-valine, methyl ester 
Y Y Y  
406 AMB-FUBINACA FUB-AMB; MMB-FUBINACA C21H22FN3O3; Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carbonyl}amino)-3-methylbutanoate 
Y Y Y  
407 AMG-1 N/A C23H30O2; (6aR,10aR)-3-(Hept-1-yn-1-yl)-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
408 AMG-14 N/A C25H36O4; (6aR,10aR)-3-(2-Hexyl-1,3-dioxolan-2-yl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
409 AMG-3 N/A C25H36O2S2; (6aR,10aR)-3-(2-Hexyl-1,3-dithiolan-2-yl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
410 AMG-36 N/A C27H40O2; (6aR,10aR)-3-(1-Hexylcyclopentyl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
411 AMG-38 N/A C26H38O2; (6aR,10aR)-3-(1-Hexylcyclobutyl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
412 AMG-41 N/A C25H36O2; (6aR,10aR)-3-(1-Hexylcyclopropyl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
413 AMG-9 N/A C26H38O2S2; (6aR,10aR)-3-(2-Hexyl-1,3-dithian-2-yl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
414 AMPPPCA N/A C26H35N3O; N-(Adamantan-1-yl)-4-methyl-1-pentyl-5-phenyl-1H-
pyrazole-3-carboxamide 
. . Y  
415 APICA SDB-001; 2NE1; JWH-018 ADAMANTYL 
CARBOXA 
C24H32N2O; N-(1-Adamantyl)-1-pentyl-1H-indole-3-carboxamide Y Y Y  
416 APINACA N/A C23H31N3O; N-(Adamantan-1-yl)-1-pentyl-1H-indazole-3-carboxamide Y Y Y  
417 APP-BINACA APP-BUTINACA C21H24N4O2; N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-butyl-1H-
indazole-3-carboxamide 
Y Y .  
418 APP-CHMICA N/A C25H29N3O2; N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-
(cyclohexylmethyl)-1H-indole-3-carboxamide 
Y . Y  
419 APP-CHMINACA WO 2009/106980 #14; PX-3 C24H28N4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide 
Y Y Y  
420 APP-FUBICA N/A C25H22FN3O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-[(4-
fluorophenyl)methyl]-1H-indole-3-carboxamide 
. . Y  
421 APP-FUBINACA N/A C24H21FN4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 
Y Y Y  
422 APP-PICA N/A C23H27N3O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-pentyl-
1H-indole-3-carboxamide; Nα-(1-Pentyl-1H-indole-3-carbonyl)-L-
phenylalaninamide 
. . Y  
423 APP-PINACA N/A C22H26N4O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-pentyl-
1H-indazole-3-carboxamide 
. . Y  
424 ATHPINACA ISOMER 1 AD-THPINACA; Adamantyl-THPINACA C24H31N3O2; 1-[(tetrahydro-2H-pyran-4-yl)methyl]-N-
tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 
Y Y Y  
425 AZ-11713908 N/A C27H32N4O3S2; N-{1-(Cyclohexylmethyl)-2-[(5-ethoxypyridin-2-
yl)methyl]-1H-benzimidazol-5-yl}-N-methylthiophene-2-sulfonamide 
. . Y  
426 BAY 38-7271 KN 38-7271 C20H21F3O5S; 3-{[(2R)-2-(Hydroxymethyl)-2,3-dihydro-1H-inden-4-
yl]oxy}phenyl 4,4,4-trifluorobutane-1-sulfonate 
. . Y  
427 BAY 59-3074 WO 2002/026702 #1 C18H13F6NO4S; 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl 4,4,4-
trifluorobutane-1-sulfonate 
. . Y  
428 BB-22 QUCHIC C25H24N2O2; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-
quinolinyl ester 
Y Y Y  
429 BE 854655 #4 N/A C21H33NO3; (6S,6aR,9R,10aR)-3-{[(2R)-Heptan-2-yl]oxy}-6-methyl-
5,6,6a,7,8,9,10,10a-octahydrophenanthridine-1,9-diol 
. . Y  
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430 BICYCLIC ANALOG XI METHYL ANALOGUE CP-55,940 C22H36O2; 2-[(1R,2R,5R)-5-Hydroxy-2-methylcyclohexyl]-5-(2-
methyloctan-2-yl)phenol 
. . Y  
431 BIM-018 N/A C23H22N2O; (Naphthalen-1-yl)(1-pentyl-1H-benzimidazol-2-
yl)methanone 
Y . Y  
432 BLKB-2 N/A C16H23N3O2; N-[(2R)-1-Hydroxypropan-2-yl]-1-pentyl-1H-indazole-3-
carboxamide 
. . Y  
433 BLKS-2 CPE; Cannabipiperidiethanone C24H28N2O2; 2-(2-Methoxyphenyl)-1-{1-[(1-methylpiperidin-2-
yl)methyl]-1H-indol-3-yl}ethan-1-one 
Y . Y  
434 BLKS-4 N/A C22H22F2N2O2; N-[(2,4-Difluorophenyl)methyl]-1-[(oxan-4-yl)methyl]-
1H-indole-3-carboxamide 
. . Y  
435 BLKS-6 N/A C25H32FN3O4; Cyclopropyl (2S)-2-({5-(2-fluorophenyl)-1-[(oxan-4-
yl)methyl]-1H-pyrazole-3-carbonyl}amino)-3,3-dimethylbutanoate 
. . Y  
436 BLKS-9 N/A C25H35FN4O3; {5-(2-Fluorophenyl)-1-[(oxan-4-yl)methyl]-1H-pyrazol-
3-yl}[(3R,5S)-4-(2-methoxyethyl)-3,5-dimethylpiperazin-1-
yl]methanone 
. . Y  
437 BML-190 Indomethacin morpholinylamide C23H23ClN2O4; 2-[1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-
3-yl]-1-(morpholin-4-yl)ethan-1-one 




N/A C23H32O4; Butyl (2S)-2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]propanoate 




N/A C25H34O4; Butyl 1-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]cyclobutane-1-carboxylate 




N/A C24H34O4; Butyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropanoate 
. . Y  
441 BZODZ-EPYR N/A C23H24N4O; 3-(3-Benzyl-1,2,4-oxadiazol-5-yl)-1-[2-(pyrrolidin-1-
yl)ethyl]-1H-indole 
. . Y  
442 C3-UR-144 N/A C19H25NO; (1-Propyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
. . Y  
443 C4-CBD N/A C20H28O2; (1′R,2′R)-4-Butyl-5′-methyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-
tetrahydro[1,1′-biphenyl]-2,6-diol 
. . Y  
444 C4-RCS-4 N/A C20H21NO2; (1-Butyl-1H-indol-3-yl)(4-methoxyphenyl)methanone Y Y Y  
445 C6-UR-144 N/A C22H31NO; (1-Hexyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
. . Y  
446 C7-UR-144 KM-X1; TMCP-020; Heptyl-UR-144 C23H33NO; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-
methanone 
Y Y Y  
447 CANNABICYCLOHEXANOL  CCH; CP 47,497 dimethyloctyl homologue C22H36O2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(2-methylnonan-2-
yl)phenol 
Y . Y  
448 CB-13 CRA13; SAB-378 C26H24O2; (Naphthalen-1-yl)[4-(pentyloxy)naphthalen-1-
yl]methanone 
Y Y Y  
449 CBL-018 NNE1 C24H23NO2; Naphthalen-1-yl 1-pentyl-1H-indole-3-carboxylate Y Y Y  
450 CBS-0550 N/A C20H23F4N3O; N-[5-tert-Butyl-2-(cyclopropylmethyl)-1-methyl-1,2-
dihydro-3H-pyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide 
. . Y  
451 CHE-CP-47,497 N/A C20H30O2; 5-(2-Cyclohexylethyl)-2-[(1S,3R)-3-
hydroxycyclohexyl]phenol 
. . Y  




Y Y Y  
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453 CHM-CP-47,497 N/A C19H28O2; 5-(Cyclohexylmethyl)-2-[(1S,3R)-3-
hydroxycyclohexyl]phenol 
. . Y  
454 CP 47,497 (C7)-CP 47,497 C21H34O2; 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-
yl)phenol 
Y Y Y  
455 CP 47,497 (C8 + C2) N/A C24H40O2; 5-(1,1-Dimethyloctyl)-2-[(1S,3S)-3-hydroxycyclohexyl]-
phenol 
. Y Y  
456 CP 55,244 N/A C26H42O3; (2R,4R,4aR,6S,8aS)-6-(Hydroxymethyl)-4-[2-hydroxy-4-(2-
methyloctan-2-yl)phenyl]decahydronaphthalen-2-ol 
Y . Y  
457 CP 55,940 N/A C24H40O3; 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
Y . Y  
458 CP-55,243 N/A C26H42O3; (2S,4S,4aS,6R,8aR)-6-(Hydroxymethyl)-4-[2-hydroxy-4-(2-
methyloctan-2-yl)phenyl]decahydronaphthalen-2-ol 
. . Y  
459 CP-56,667 N/A C24H40O3; 2-[(1S,2S,5S)-5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
460 CUMYL-4CN-B7AICA N/A C22H24N4O; 1-(4-cyanobutyl)-N-(2-phenylpropane-2-yl)-7-azaindole-3-
carboxamide 
Y Y Y  
461 CUMYL-CH-MEGACLONE N/A C27H30N2O; 5-(cyclohexylmethyl)-2-(2-phenylpropan-2-yl)-2,5-
dihydro-1H-pyrido[4,3-b]indol-1-one 
Y Y .  
462 CUMYL-FUBICA N/A C25H23FN2O; 1-[(4-Fluorophenyl)methyl]-N-(2-phenylpropan-2-yl)-1H-
indole-3-carboxamide 
. . Y  
463 CUMYL-PEGACLONE 2-Cumyl-5-pentyl-γ-carbolin-1-one C25H28N2O; 5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-
pyrido[4,3-b]indol-1-one 
Y Y Y  
464 CUMYL-PINACA SGT-24 C22H27N3O; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-
carboxamide 
Y Y Y  
465 CUMYL-TFBICA SGT-262 C22H23F3N2O: N-(2-Phenylpropan-2-yl)-1-(4,4,4-trifluorobutyl)-1H-
indole-3-carboxamide 










. . Y  
468 DESACETYL-LEVONANTRADOL N/A C25H33NO3; (6S,6aR,9R,10aR)-6-methyl-3-[(2R)-5-phenylpentan-2-
yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridine-1,9-diol 
. . Y  
469 DESPENTYL-UR-144 DP-UR-144 C16H19NO; (1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone Y . .  
470 DIMETHYL CP-47,497-C8  5,5-Dimethyl-(C8) CP 47,497 C24H40O2; rel-2-((1R,5S)-5-hydroxy-3,3-dimethylcyclohexyl)-5-(2-
methylnonan-2-yl)phenol 
Y . Y  




Y . Y  
472 DMBA-CHMINACA N/A C21H29N3O3; 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoic acid 
Y Y .  
473 DMP-PICA N/A C22H26N2O; N-(2,6-Dimethylphenyl)-1-pentyl-1H-indole-3-
carboxamide 
. . Y  
474 EA-1465 N/A C25H38O2; 6,6,9-Trimethyl-3-(nonan-2-yl)-7,8,9,10-tetrahydro-6H-
dibenzo[b,d]pyran-1-ol 
. . Y  
475 EA-1543 N/A C25H39O4P; Propan-2-yl 6,6,9-trimethyl-3-pentyl-7,8,9,10-tetrahydro-
6H-dibenzo[b,d]pyran-1-yl methylphosphonate 
. . Y  
476 EA-2233-2 N/A C27H40O3; (9R)-6,6,9-Trimethyl-3-[(2S,3R)-3-methyloctan-2-yl]-
7,8,9,10-tetrahydro-6H-dibenzo[b,d]pyran-1-yl acetate 
. . Y  
477 EAM-2201 JWH 210 N-(5-fluoropentyl) analog C26H26FNO; (4-ethyl-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-
methanone 
Y Y Y  
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478 EG-018 N/A C28H25NO; naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone Y Y Y  
479 EG-2201 N/A C28H24FNO; (9-(5-fluoropentyl)-9H-carbazol-3-yl)(naphthalen-1-
yl)methanone 
Y Y Y  
480 
 
EMB-FUBINACA AEB-FUBINACA; FU-AEB; FUB-AEB C22H24FN3O3; ethyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
valinate 
Y Y Y  
481 EPI-CP 55,940 N/A C24H40O3; 2-[(1R,2R,5S)-5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
482 ETHYL 5-[2,6-DIHYDROXY-4-(2-METHYL-2-
OCTANYL)PHENYL]NICOTINATE 
US 2004/0087590 #5 C23H31NO4; Ethyl 5-[2,6-dihydroxy-4-(2-methyloctan-2-
yl)phenyl]pyridine-3-carboxylate 
. . Y  
483 FAB-144 (Indazole) XLR-11; 5F-UR-144 indazole C20H27FN2O; [1-(5-Fluoropentyl)-1H-indazol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
Y . Y  
484 FDU-NNE1 FDU-MN-24; FDU-NNEI C26H19FN2O; 1-[(4-Fluorophenyl)methyl]-N-(naphthalen-1-yl)-1H-
indole-3-carboxamide 
Y . Y  
485 FDU-PB-22 N/A C26H18FNO2; Naphthalen-1-yl-1-(4-fluorobenzyl)-1H-indole-3-
carboxylate 
Y Y Y  
486 FENCHYL-PINACA N/A C23H33N3O; 1-Pentyl-N-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indazole-3-carboxamide 
. . Y  
487 FP-CP 47,497 N/A C17H25FO2; 5-(5-Fluoropentyl)-2-[(1S,3R)-3-hydroxycyclohexyl]phenol . . Y  
488 FUB-144 FUB-UR-144 C23H24FNO; C23H24FNO; (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
489 FUB-2201 N/A C19H26FN3O2 . . Y  
490 FUB-JWH-018 N/A C26H18FNO; {1-[(4-Fluorophenyl)methyl]-1H-indol-3-yl}(naphthalen-1-
yl)methanone 
Y Y Y  
491 FUB-NPB-22 (Indazole) FUB-PB-22 C24H16FN3O2; Quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carboxylate 
Y Y Y  
492 FUB-PB-22 QCBL-Bz-F; MN-27 C25H17FN2O2; quinolin-8-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-
carboxylate 
Y Y Y  
493 FUBIMINA (Benzimidazole) AM-2201; FTHJ; BZ-2201 C23H21FN2O; [1-(5-Fluoropentyl)-1H-benzimidazol-2-yl](naphthalen-1-
yl)methanone 
Y Y Y  
494 GSK-554418A N/A C19H19ClN4O2; [4-(3-Chloroanilino)-1-methyl-1H-pyrrolo[3,2-
c]pyridin-7-yl](morpholin-4-yl)methanone 
. . Y  
495 GW-405,833 L-768,242 C23H24Cl2N2O3; (2,3-Dichlorophenyl){5-methoxy-2-methyl-3-[2-
(morpholin-4-yl)ethyl]-1H-indol-1-yl}methanone 
. . Y  
496 GW-842,166X N/A C18H17Cl2F3N4O2; 2-(2,4-Dichloroanilino)-N-[(oxan-4-yl)methyl]-4-
(trifluoromethyl)pyrimidine-5-carboxamide 
. . Y  
497 HHC N/A C21H32O2; (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,8,9,10,10a-
hexahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
498 HU-210 N/A C25H38O3; 9-(HYDROXYMETHYL)-6,6-DIMETHYL-3-(2-METHYLOCTAN-
2-YL)-6A,7,10,10A-TETRAHYDROBENZO[C]CHROMEN-1-OL 
Y Y Y  
499 HU-211 N/A C25H38O3; (6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-
methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
Y . Y  
500 HU-239 N/A C25H36O4; (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-9-carboxylic acid 
. . Y  
501 HU-308 N/A C27H42O3; {(4S)-4-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-
dimethylbicyclo[3.1.1]hept-2-en-2-yl}methanol 
Y . Y  
502 HU-320 N/A C25H36O4; (1S,6S)-2′,6′-Dihydroxy-4′-(2-methyloctan-2-yl)-6-(prop-1-
en-2-yl)-1,4,5,6-tetrahydro[1,1′-biphenyl]-3-carboxylic acid 
. . Y  
503 HU-331 N/A C21H28O3; 3-Hydroxy-2-[(1R)-6-isopropenyl-3-methyl-cyclohex-2-en-1-
yl]-5-pentyl-1,4-benzoquinone 
Y Y Y  
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504 HU-336 N/A C21H28O3; (6aR,10aR)-6,6,9-Trimethyl-3-pentyl-6a,7,10,10a-
tetrahydro-1H-dibenzo[b,d]pyran-1,4(6H)-dione 
. . Y  
505 HU-345 N/A C21H24O3; 6,6,9-Trimethyl-3-pentyl-1H-dibenzo[b,d]pyran-1,4(6H)-
dione 
. . Y  
506 HU-433 N/A C27H42O3; {(4R)-4-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-
dimethylbicyclo[3.1.1]hept-2-en-2-yl}methanol 
. . Y  
507 HUF-101 4'-F-CBD; 4'-Fluorocannabidiol C21H29FO2; (1′R,2′R)-3-Fluoro-5′-methyl-4-pentyl-2′-(prop-1-en-2-yl)-
1′,2′,3′,4′-tetrahydro[1,1′-biphenyl]-2,6-diol 
. . Y  
508 INVERSE-JWH-018 N/A C24H23NO; (Naphthalen-1-yl)(3-pentyl-1H-indol-1-yl)methanone . . Y  
509 IPO-33 N/A C20H22N2O; 1-(1-Pentyl-1H-indazol-3-yl)-2-phenylethan-1-one . . Y  
510 JNJ-42165279 N/A C18H17ClF2N4O3; N-(4-Chloropyridin-3-yl)-4-[(2,2-difluoro-2H-1,3-
benzodioxol-5-yl)methyl]piperazine-1-carboxamide 
. . Y  
511 JTE 7-31 N/A C22H28N2O3; 2-[2-(4-Hydroxyphenyl)ethyl]-5-methoxy-4-
(pentylamino)-2,3-dihydro-1H-isoindol-1-one 
. . Y  
512 JTE-907 N/A C24H26N2O6; N-[(2H-1,3-Benzodioxol-5-yl)methyl]-7-methoxy-2-oxo-
8-(pentyloxy)-1,2-dihydroquinoline-3-carboxamide 
Y Y Y  
513 JWH-001 N/A C17H22N2O2; 1-{2-Methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-
yl}ethan-1-one 
. . Y  
514 JWH-002 N/A C20H26N2O2; 3-Methyl-1-{2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-
indol-3-yl}but-2-en-1-one 
. . Y  
515 JWH-007 N/A C25H25NO; (2-methyl-1-pentyl-1H-indol-3-yl)-1-naphthalenyl-
methanone 
Y Y Y  
516 JWH-015 N/A C23H21NO; (2-Methyl-1-propyl-1H-indol-3-yl)-1-
naphthalenylmethanone 
Y Y Y  
517 JWH-018 AM-678; JWH-018 C24H23NO; Naphthalen-1-yl-(1-pentylindol-3-yl)methanone Y Y Y  
518 JWH-018 ADAMANTOYL DERIVATIVE AB-001  C24H31NO; 1-Pentyl-3-(adamant-1-oyl)indole Y Y Y  
519 JWH-018 AZAINDOLE ANALOGUE N/A C23H22N2O; Naphthalen-1-yl-(1-pentyl-1H-7-azaindol-3-yl)methanone Y . .  
520 JWH-018 N-PENTANOIC ACID JWH-018 N-Pentyl-5-carboxylic Acid C24H21NO3; 5-[3-(Naphthalene-1-carbonyl)-1H-indol-1-yl]pentanoic 
acid 
. . Y  
521 JWH-018 SULFONIUM BROMIDE N/A C24H23OS; (1-Bromo-1-pentyl-1H-1-benzothiophen-3-yl)(naphthalen-
1-yl)methanone 
. . Y  
522 JWH-018 THIOKETONE N/A C24H23NS (Naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanethione . . Y  
523 JWH-019 1-Hexyl-3-(1-naphthoyl)indole C25H25NO; 1-Hexyl-3-(1-naphthoyl)indole Y Y Y  
524 JWH-020 N/A C26H27NO; (1-Heptyl-1H-indol-3-yl)(naphthalen-1-yl)methanone Y . Y  
525 JWH-022 1-(4-Pentene-yl)-3-(1-naphthoyl)indole C24H21NO; 1-(4-Pentene-yl)-3-(1-naphthoyl)indole Y Y Y  
526 JWH-030 N/A C20H21NO; (Naphthalen-1-yl)(1-pentyl-1H-pyrrol-3-yl)methanone Y Y Y  
527 JWH-051 N/A C25H38O2; [(6aR,10aR)-6,6-Dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-9-yl]methanol 
. . Y  
528 JWH-071 N/A C21H17NO; (1-ethyl-1H-indol-3-yl)-1-naphthalenyl-methanone Y Y Y  
529 JWH-072 N/A C22H19NO; (Naphthalen-1-yl)(1-propyl-1H-indol-3-yl)methanone . . Y  
530 JWH-073 N/A C23H21NO; (1-Butyl-1H-indol-3-yl)(1-naphthyl)methanone Y Y Y  
Short Running Title of the Article Journal Name, 2014, Vol. 0, No. 0    33 
531 JWH-073 METHYL DERIVATIVE JWH-073 methyl derivative C24H23NO; 4-methyl-naphthalen-1-yl-(1-butylindol-3-yl)methanone; 1-
Butyl-3-(1-(4-methyl)naphthoyl)indol; (1-Butyl-1H-indol-3-yl)-1-(4-
methyl)naphthalenylmethanone; (1-butyl- 1H-indol-3-yl)(4-
methylnaphthalen-1-yl)methanone; JWH-073 methyl derivative 
Y Y Y  
532 JWH-080 N/A C24H23NO2; (1-Butyl-1H-indol-3-yl)(4-methoxynaphthalen-1-
yl)methanone 
. . Y  
533 JWH-081 N/A C25H25NO2; 4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-
yl)methanone 
Y Y Y  
534 JWH-082 N/A C26H27NO2; (1-Hexyl-1H-indol-3-yl)(4-methoxynaphthalen-1-
yl)methanone 
. . Y  
535 JWH-098 N/A C26H27NO2; (4-Methoxynaphthalen-1-yl)(2-methyl-1-pentyl-1H-indol-
3-yl)methanone 
. . Y  
536 JWH-116 N/A C26H27NO; (2-Ethyl-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
537 JWH-121 N/A C24H23NO; (1-Butyl-1H-indol-3-yl)(4-methylnaphthalen-1-
yl)methanone 
. . Y  
538 JWH-122 N/A C25H25NO; (4-methyl-1-naphthyl)-(1-pentylindol-3-yl)methanone Y Y Y  
539 JWH-122 (5-METHYL-NAPHTYL ISOMER) N/A C25H25NO; (5-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
Y . .  




Y Y Y  
541 JWH-133 N/A C22H32O; (6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-2-yl)-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran 
. . Y  
542 JWH-145 N/A C26H25NO; (Naphthalen-1-yl)(1-pentyl-5-phenyl-1H-pyrrol-3-
yl)methanone 
Y Y Y  
543 JWH-147 N/A C27H27NO; (1-Hexyl-5-phenyl-1H-pyrrol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
544 JWH-149 N/A C26H27NO; (4-Methylnaphthalen-1-yl)(2-methyl-1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
545 JWH-166 N/A C25H25NO2; (6-Methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
546 JWH-167 N/A C21H23NO; 1-(1-Pentyl-1H-indol-3-yl)-2-phenylethan-1-one . . Y  
547 JWH-175 N/A C24H25N; 3-[(Naphthalen-1-yl)methyl]-1-pentyl-1H-indole Y . Y  
548 JWH-176 N/A C25H24; 1-[(E)-(3-Pentyl-1H-inden-1-ylidene)methyl]naphthalene . . Y  
549 JWH-181 N/A C28H31NO; (2-Methyl-1-pentyl-1H-indol-3-yl)(4-propylnaphthalen-1-
yl)methanone 
. . Y  
550 JWH-182 1-pentyl-3-(4-propyl-1-naphthoyl)indole C27H29NO; (1-pentylindol-3-yl)-(4-propylnaphthalen-1-yl)methanone Y Y Y  
551 JWH-184 N/A C25H27N; 3-[(4-Methylnaphthalen-1-yl)methyl]-1-pentyl-1H-indole . . Y  
552 JWH-185 N/A C25H27NO; 3-[(4-Methoxynaphthalen-1-yl)methyl]-1-pentyl-1H-indole . . Y  
553 JWH-193 N/A C26H26N2O2; (4-Methylnaphthalen-1-yl){1-[2-(morpholin-4-yl)ethyl]-
1H-indol-3-yl}methanone 
. . Y  
554 JWH-198 N/A C26H26N2O3; (4-Methoxynaphthalen-1-yl){1-[2-(morpholin-4-yl)ethyl]-
1H-indol-3-yl}methanone 
. . Y  
555 JWH-200 N/A C25H24N2O2; 1-(2-Morpholin-4-ylethyl)-3-(1naphthoyl)indole Y Y Y  
556 JWH-201 N/A C22H25NO2; 2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-
one 
Y . Y  
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557 JWH-203 1-Pentyl-3-(2-chlorophenylacetyl)indole C21H22ClNO; 1-Pentyl-3-(2-chlorophenylacetyl)indole Y Y Y  
558 JWH-204 N/A C22H24ClNO; 2-(2-Chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
559 JWH-206 JWH-206; CHEMBL188819; 864445-58-9 C21H22ClNO; 2-(4-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-
one 
Y . Y  
560 JWH-207 JWH-207; CHEMBL187813; D0GD9G C22H24ClNO; 2-(4-Chlorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
561 JWH-208 JWH-208; CHEMBL187354; JWH 251 4-
methylp 
C22H25NO; 2-(4-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one . . Y  
562 JWH-209 JWH-209; CHEMBL187771; D0YM8O C23H27NO; 1-(2-Methyl-1-pentyl-1H-indol-3-yl)-2-(4-
methylphenyl)ethan-1-one 
. . Y  
563 JWH-210 N/A C26H27NO; 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; 1-
Pentyl-3-(4-ethyl-1-naphthoyl)indole 
Y Y Y  
564 JWH-211 CHEMBL562350; JWH-211; 824959-72-0 C25H25NO; (4-Ethylnaphthalen-1-yl)(2-methyl-1-propyl-1H-indol-3-
yl)methanone 
. . Y  
565 JWH-213 N/A C27H29NO; (4-Ethylnaphthalen-1-yl)(2-methyl-1-pentyl-1H-indol-3-
yl)methanone 
Y . Y  
566 JWH-220 N/A C26H26; 1-Methyl-4-[(E)-(3-pentyl-1H-inden-1-
ylidene)methyl]naphthalene 
. . Y  




. . Y  
568 JWH-240 N/A C28H31NO; (4-Butylnaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
569 JWH-249 N/A C21H22BrNO; 2-(2-Bromophenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-
one 
. . Y  
570 JWH-250 N/A C22H25NO2; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone Y Y Y  
571 JWH-251 N/A C22H25NO; 1-Pentyl-3-(2-methylphenylacetyl)indole Y Y Y  
572 JWH-253 JWH-253; CHEMBL188887; D01IUI C23H27NO2; 2-(3-Methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
573 JWH-258 N/A C26H27NO2; (4-Ethoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
574 JWH-267 1-Pentyl-3-(2-methoxy-1-
naphthoyl)indole 
C25H25NO2; 1-Pentyl-3-(2-methoxy-1-naphthoyl)indole Y . Y  
575 JWH-302 JWH-302; CHEMBL186674; JWH 302 C22H25NO2; 2-(3-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone Y Y Y  
576 JWH-305 JWH-305; CHEMBL187559; D0IW4Q C22H24BrNO; 2-(2-Bromophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
577 JWH-306 JWH-306; CHEMBL361088; D0L5IM C23H27NO2; 2-(2-Methoxyphenyl)-1-(2-methyl-1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
578 JWH-307 N/A C26H24FNO; [5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-
1-yl)methanone 
Y Y Y  
579 JWH-308 N/A C26H24FNO; [5-(4-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-
1-yl)methanone 
. . Y  
580 JWH-309 N/A C30H27NO; (Naphthalen-1-yl)[5-(naphthalen-1-yl)-1-pentyl-1H-pyrrol-
3-yl]methanone 
. . Y  
581 JWH-311 JWH-311; CHEMBL187883; D02UEJ C21H22FNO; 2-(2-Fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one . . Y  
582 JWH-312 JWH-312; CHEMBL189545; D0RI8G C21H22FNO; 2-(3-Fluorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one . . Y  
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583 JWH-316 N/A C22H24FNO; 2-(4-Fluorophenyl)-1-(2-methyl-1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
584 JWH-317 N/A C22H23NO3; 2-(2H-1,3-Benzodioxol-5-yl)-1-(1-pentyl-1H-indol-3-
yl)ethan-1-one 
. . Y  
585 JWH-337 N/A C24H40O2; (1R,3R,4R)-4-(3-Hydroxypropyl)-3-[4-(2-methyloctan-2-
yl)phenyl]cyclohexan-1-ol 
. . Y  
586 JWH-344 N/A C23H38O2; (1R,3R,4R)-4-(3-Hydroxypropyl)-3-[4-(2-methylheptan-2-
yl)phenyl]cyclohexan-1-ol 
. . Y  
587 JWH-346 N/A C27H27NO; [5-(3-Methylphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-
1-yl)methanone 
. . Y  
588 JWH-365 N/A C28H29NO; [5-(2-Ethylphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-
yl)methanone 
. . Y  
589 JWH-366 N/A C25H24N2O; (Naphthalen-1-yl)[1-pentyl-5-(pyridin-3-yl)-1H-pyrrol-3-
yl]methanone 
. . Y  
590 JWH-367 N/A C27H27NO2; [5-(3-Methoxyphenyl)-1-pentyl-1H-pyrrol-3-
yl](naphthalen-1-yl)methanone 
. . Y  
591 JWH-368 N/A C26H24FNO; [5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-
1-yl)methanone 
Y Y Y  
592 JWH-370 N/A C27H27NO; [5-(2-Methylphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-
1-yl)methanone 
Y Y Y  
593 JWH-372 N/A C27H24F3NO; (Naphthalen-1-yl){1-pentyl-5-[2-
(trifluoromethyl)phenyl]-1H-pyrrol-3-yl}methanone 
. . Y  
594 JWH-377 JWH-018 2'-naphthyl isomer C24H23NO; (Naphthalen-2-yl)(1-pentyl-1H-indol-3-yl)methanone Y . Y  
595 JWH-387 N/A C24H22BrNO; (4-Bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 





Y Y Y  
597 JWH-408 N/A C25H25NO2; (6-Methoxynaphthalen-2-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
598 JWH-409 N/A C26H27NO2; (6-Methoxynaphthalen-2-yl)(2-methyl-1-pentyl-1H-indol-
3-yl)methanone 
. . Y  
599 JWH-410 N/A C25H25NO2; (1-Butyl-2-methyl-1H-indol-3-yl)(6-methoxynaphthalen-2-
yl)methanone 
. . Y  
600 JWH-412 N/A C24H22FNO; (4-Fluoronaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
Y Y Y  
601 JWH-421 N/A C24H22INO; (4-Iodonaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
602 JWH-424 N/A C24H22BrNO; (8-Bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone 
. . Y  
603 JWH-444 N/A C24H22BrNO; (5-Bromo-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
604 JWH-452 N/A C24H22INO; (5-Iodo-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
605 JZL-184 N/A C27H24N2O9; 4-Nitrophenyl 4-[bis(2H-1,3-benzodioxol-5-
yl)(hydroxy)methyl]piperidine-1-carboxylate 
. . Y  
606 JZL-195 N/A C24H23N3O5; 4-Nitrophenyl 4-[(3-phenoxyphenyl)methyl]piperazine-
1-carboxylate 
. . Y  
607 KM-233 N/A C25H30O2; (6aR,10aR)-6,6,9-Trimethyl-3-(2-phenylpropan-2-yl)-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
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608 L-759,633 N/A C26H40O2; (6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2-methyloctan-2-
yl)-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran 
. . Y  
609 L-759,656 N/A C26H40O2; (6aR,10aR)-1-Methoxy-6,6-dimethyl-9-methylidene-3-(2-
methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran 
. . Y  
610 LASSBIO-881 N/A C23H27N3O6; N′-[(E)-(3,5-Di-tert-butyl-4-hydroxyphenyl)methylidene]-
6-nitro-2H-1,3-benzodioxole-5-carbohydrazide 
. . Y  
611 LBP-1 N/A C23H29ClN6O3; 2-{4-[(3-{7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-yl}-
1,2,4-oxadiazol-5-yl)methyl]piperazin-1-yl}acetamide 
. . Y  
612 LEVONANTRADOL CP 50,556-1; L-Nantradol C27H35NO4;(6S,6aR,9R,10aR)-9-Hydroxy-6-methyl-3-{[(2R)-5-
phenylpentan-2-yl]oxy}-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-
yl acetate 
. . Y  
613 LH-21 N/A C20H20Cl3N3; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-
1,2,4-triazole 
. . Y  
614 LTI-701 N/A C20H21FN2O; 1-(5-fluoropentyl)-N-phenyl-1H-indole-3-carboxamide Y Y Y  
615 LY2183240 N/A C17H17N5O; 5-[([1,1′-Biphenyl]-4-yl)methyl]-N,N-dimethyl-1H-
tetrazole-1-carboxamide 
Y Y Y  
616 M-CHMIC N/A C17H20NO2; methyl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate Y Y Y  
617 M5FPIC M-5F-PIC C15H18FNO2; Methyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate Y Y Y  
618 MAM-1220 N/A C27H28N2O; (4-Methylnaphthalen-1-yl){1-[(1-methylpiperidin-2-
yl)methyl]-1H-indol-3-yl}methanone 
. . Y  
619 MAM-2201 N/A C25H24FNO; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(4-methyl-naphthalen-
1-yl)methanone 
Y Y Y  
620 MAM-2201 INDAZOLE ANALOGUE N/A C24H23FN2O; [1-(5-Fluoropentyl)-1H-indazol-3-yl](4-
methylnaphthalen-1-yl)methanone 
. . Y  
621 MAM-2201 N-(2-FLUOROPENTYL) N/A C25H24FNO; (1-(2-fluoropentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-
yl)methanone 
Y . .  
622 MAM-2201 N-(3-FLUOROPENTYL) N/A C25H24FNO; (1-(3-fluoropentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-
yl)methanone 
Y . .  
623 MAM-2201 N-(4-FLUOROPENTYL) N/A C25H24FNO; (1-(4-fluoropentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-
yl)methanone 
Y . .  
624 MAM-2201 N-(4-HYDROXYPENTYL) N/A C25H25NO2; (1-(4-hydroxypentyl)-1H-indol-3-yl)(4-methylnaphthalen-
1-yl)methanone 
Y . .  
625 MAM-2232 N/A C25H22N2O; 5-[3-(4-Methylnaphthalene-1-carbonyl)-1H-indol-1-
yl]pentanenitrile 





Y Y .  




Y Y Y  
628 MDA 19 N/A C21H23N3O2; (3Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)benzohydrazide Y Y Y  
629 MDA-77 N/A C21H23N3O3; N′-(6-Methoxy-2-oxo-1-pentyl-1,2-dihydro-3H-indol-3-
ylidene)benzohydrazide 
. . Y  
630 MDMB-4EN-PINACA N/A C20H27N3O3; methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-
3-carboxamido)butanoate 
Y Y .  
631 MDMB-CHMCZCA EGMB-CHMINACA C27H34N2O3; methyl (S)-2-(9-(cyclohexylmethyl)-9H-carbazole-3-
carboxamido)-3,3-dimethylbutanoate 
Y Y Y  




Y Y Y  
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633 MDMB-CHMINACA MDMB(N)-CHM C22H31N3O3; Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazole-3-
carbonyl]amino}-3,3-dimethylbutanoate 
Y . Y  
634 MDMB-FUBICA N/A C23H25FN2O3; methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indol-3-
yl}formamido)-3,3-dimethylbutanoate 
Y Y Y  




Y Y Y  




Y Y Y  
637 ME-CP 47,497 N/A C18H27NO3; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-[2-(morpholin-4-
yl)ethyl]phenol 
. . Y  
638 MENABITAN SP-204; menabitan hydrochloride C37H56N2O3; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-2-(prop-2-yn-1-yl)-
1,3,4,5-tetrahydro-2H-[1]benzopyrano[4,3-c]pyridin-10-yl 2-methyl-4-
(2-methylpiperidin-1-yl)butanoate 
. . Y  
639 MEP-CHMICA N/A C22H30N2O3; methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
carboxamido)pentanoate 
Y . .  
640 MEP-FUBICA N/A C22H23FN2O3; Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-
carbonyl}amino)pentanoate 
Y . Y  
641 MEPIRAPIM N/A C19H27N3O; 1-(1-pentylindol-3-carbonyl)-4-methyl-piperazine3-[(4-
methylpiperazin-1-yl)carbonyl]-1-pentyl-1H-indole(4-methylpiperazin-
1-yl)(1-pentyl-1H-indol-3-yl)methanone 
Y Y Y  
642 META-RCS-4 RCS-3 C21H23NO2; (3-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone Y . Y  
643 METHANANDAMIDE. AM-356 C23H39NO2; (5Z,8Z,11Z,14Z)-N-[(2R)-1-Hydroxypropan-2-yl]icosa-
5,8,11,14-tetraenamide. 

















. . Y  
646 METHYL (3Z)-3-[(2-METHOXYPHENYL)IMINO]-2-THIA-4-
AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE 
N/A C18H24N2OS3; Methyl (3Z)-3-[(2-methoxyphenyl)imino]-2-thia-4-
azaspiro[5.5]undecane-4-carbodithioate 
. . Y  
647 METHYL (3Z)-3-[(3-TERT-BUTYL-1,2-OXAZOL-5-YL)IMINO]-2-
OXA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE 
N/A C18H27N3O2S2; Methyl (3Z)-3-[(3-tert-butyl-1,2-oxazol-5-yl)imino]-2-
oxa-4-azaspiro[5.5]undecane-4-carbodithioate 
. . Y  
648 METHYL (3Z)-3-[(4-TERT-BUTYL-1,3-THIAZOL-2-YL)IMINO]-2-
OXA-4-AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE 
N/A C18H27N3OS3; Methyl (3Z)-3-[(4-tert-butyl-1,3-thiazol-2-yl)imino]-2-
oxa-4-azaspiro[5.5]undecane-4-carbodithioate 
. . Y  
649 METHYL (3Z)-3-[(NAPHTHALEN-1-YL)IMINO]-2-OXA-4-
AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE 
N/A C21H24N2OS2; Methyl (3Z)-3-[(naphthalen-1-yl)imino]-2-oxa-4-
azaspiro[5.5]undecane-4-carbodithioate 
. . Y  
650 METHYL (3Z)-3-[(NAPHTHALEN-1-YL)IMINO]-2-THIA-4-
AZASPIRO[5.5]UNDECANE-4-CARBODITHIOATE 
N/A C21H24N2S3; Methyl (3Z)-3-[(naphthalen-1-yl)imino]-2-thia-4-
azaspiro[5.5]undecane-4-carbodithioate 




N/A C24H31NO4; Methyl 1-[(oxan-4-yl)methyl]-3-(2,2,3,3-
tetramethylcyclopropane-1-carbonyl)-1H-indole-6-carboxylate 
. . Y  
652 METHYL 6-(2-HYDROXY-3',5'-DIMETHYL[1,1'-BIPHENYL]-4-YL)-
6-METHYLHEPTANOATE 
N/A C23H30O3; METHYL 6-(2-HYDROXY-3',5'-DIMETHYL[1,1'-BIPHENYL]-4-
YL)-6-METHYLHEPTANOATE 
. . Y  




C16H13FN2O2; methyl 1-(4-fluorobenzyl)-1H-indazole-3-carboxylate Y . .  
654 MK-4409 N/A C23H18ClFN2O2S; 2-(4-{5-[(5-Chloropyridin-2-yl)sulfanyl]-2-(4-
fluorophenyl)-1,3-oxazol-4-yl}phenyl)propan-2-ol 
. . Y  
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655 MK-9470 N/A C29H33N3O3; N-[(2S,3S)-3-(3-Cyanophenyl)-4-(4-ethoxyphenyl)butan-
2-yl]-2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide 
. . Y  
656 MMB-022 AMB-4en-PICA C20H26N2O3; methyl (1-(pent-4-en-1-yl)-1H-indole-3-carbonyl)-L-
valinate; 
. Y Y  
657 MMB-CHMICA AMB-CHMICA C22H30N2O3 Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-
carbonyl]amino}-3-methylbutanoate 





Y . .  
659 MMB-PINACA N/A C19H27N3O3; Methyl-3-methyl-2-(1-pentyl-1H-indazole-3-
carboxamido)butanoate 
Y . .  
660 MN-18 N/A C23H23N3O; N-(naphthalen-1-yl)-1-pentyl-1H-indazole-3-carboxamide Y Y Y  
661 MN-25 UR-12 C26H37N3O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[(1S,2S,4R)-
1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-carboxamide 
. . Y  
662 MO-CHMINACA MO-AMB C22H30N2O4; 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl 1-
(cyclohexylmethyl)-1H-indazole-3-carboxylate  
Y Y Y  
663 MPM-CP 47,497 N/A C19H29NO2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-[(1-methylpiperidin-2-
yl)methyl]phenol 
. . Y  
664 MPP-CHMICA N/A C26H30N2O3; Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-
carbonyl]amino}-3-phenylpropanoate 
. . Y  
665 MPP-CHMINACA N/A C25H29N3O3; Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indazole-3-
carbonyl]amino}-3-phenylpropanoate 
. . Y  
666 MPP-FUBICA N/A C26H23FN2O3; Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-indole-
3-carbonyl}amino)-3-phenylpropanoate 
. . Y  
667 MPP-FUBINACA N/A C25H22FN3O3; Methyl (2S)-2-({1-[(4-fluorophenyl)methyl]-1H-
indazole-3-carbonyl}amino)-3-phenylpropanoate 





















Y Y Y  




Y . Y  
672 N-(6-QUINOLINYL)-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE N/A C22H22N4O; 1-pentyl-N-(quinolin-6-yl)-1H-indazole-3-carboxamide Y . .  
673 N-(ADAMANTAN-1-YL)-2-OXO-1-PENTYL-1,2-
DIHYDROQUINOLINE-3-CARBOXAMIDE 
N/A C25H32N2O2;  N-(Adamantan-1-yl)-2-oxo-1-pentyl-1,2-
dihydroquinoline-3-carboxamide 






















. . Y  
































Y . .  
















. . Y  
688 N-[3-(2-METHOXYETHYL)-1,3-BENZOTHIAZOL-2-YLIDENE]-
2,2,3,3-TETRAMETHYLCYCLOPROPANE-1-CARBOXAMIDE 
US 2008/058335 #62 C18H24N2O2S; N-[3-(2-Methoxyethyl)-1,3-benzothiazol-2(3H)-ylidene]-
2,2,3,3-tetramethylcyclopropane-1-carboxamide 
. . Y  
689 N-[3-(2-METHOXYETHYL)-4,5-DIMETHYL-1,3-THIAZOL-2-
YLIDENE]NAPHTHALENE-1-CARBOXAMIDE 
US 2008/058335 #16 C19H20N2O2S; N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-
ylidene]naphthalene-1-carboxamide 
. . Y  
690 N-[3-BUTYL-5-(2-HYDROXYPROPAN-2-YL)-4-METHYL-1,3-
THIAZOL-2-YLIDENE]-5-CHLORO-2-METHOXYBENZAMIDE 
US 2008/058335 #313 C19H25ClN2O3S; N-[3-Butyl-5-(2-hydroxypropan-2-yl)-4-methyl-1,3-
thiazol-2(3H)-ylidene]-5-chloro-2-methoxybenzamide 









































. . Y  
699 N-METHYL-LEVONANTRADOL N/A C28H37NO4; (6S,6aR,9R,10aR)-9-Hydroxy-5,6-dimethyl-3-{[(2R)-5-
phenylpentan-2-yl]oxy}-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-
yl acetate 





Y . .  
















. . Y  
704 NABAZENIL SP-175; Nabazelinum C35H55NO3; 6,6,9-Trimethyl-3-(3-methyloctan-2-yl)-7,8,9,10-
tetrahydro-6H-dibenzo[b,d]pyran-1-yl 4-(azepan-1-yl)butanoate 
. . Y  
705 NABILONE N/A C24H36O3; rac-(6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-
2-yl)-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-one 
. . Y  





. . Y  
707 NABIXIMOLS Sativex combination of Tetrahydrocannabinol and Cannabinoid . . Y  
708 NABOCTATE SP-325 C33H53NO3; (6,6,9-trimethyl-3-nonan-2-yl-7,8,9,10-
tetrahydrobenzo[c]chromen-1-yl) 4-(diethylamino)butanoate 
. . Y  





Y . .  
711 NAPIE N/A C25H25NO; 2-(Naphthalen-1-yl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one . . Y  
712 NBB-22 N/A C24H23N3O2; Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indazole-3-
carboxylate 
. . Y  
713 NESS-040C5 N/A C27H33N3OS; 1-[(4-Methylphenyl)methyl]-N-[5-methyl-2-(propan-2-
yl)cyclohexyl]-1,4-dihydrothieno[3′,2′:4,5]cyclopenta[1,2-c]pyrazole-3-
carboxamide 
. . Y  
714 NM-2201 CBL-2201 C24H22FNO2; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate 
Y Y Y  
715 NM-CHM N/A C26H25NO2; Naphthalen-1-yl 1-(cyclohexylmethyl)-1H-indole-3-
carboxylate 
. . Y  
716 NMP-7 N/A C23H28N2O; (9-Pentyl-9H-carbazol-3-yl)(piperidin-1-yl)methanone . . Y  
717 NNEI 2-INDAZOLE ISOMER N-(naphthalen-1-yl)-2-pentyl-2H-
indazole-3-carboxamide; NNE1 2’-
indazole isomer 
C23H23N3O; N-(naphthalen-1-yl)-2-pentyl-2H-indazole-3-carboxamide Y . .  
718 NNL-1 N/A C17H23FN4O2; N-[(2S)-1-Amino-1-oxobutan-2-yl]-1-(5-fluoropentyl)-
1H-pyrrolo[2,3-b]pyridine-3-carboxamide 
. . Y  
719 NNL-2 BZP-2201; 5F-BEPIRAPIM C25H30FN3O; (4-Benzylpiperazin-1-yl)[1-(5-fluoropentyl)-1H-indol-3-
yl]methanone 
. . Y  
720 NNL-3 N/A C19H18FN5O2; 1-{[1-(5-Fluoropentyl)-1H-pyrrolo[2,3-b]pyridine-3-
carbonyl]oxy}-1H-benzotriazole 
. . Y  
721 NONABINE BRL-4664 C25H33NO2; 2,2-Dimethyl-7-(3-methyloctan-2-yl)-4-(pyridin-4-yl)-2H-
1-benzopyran-5-ol 
. . Y  
722 O-1057 N/A C32H46N2O4; (6aR,10aR)-3-(6-Cyano-2-methylhexan-2-yl)-6,6,9-
trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl 4-
(morpholin-4-yl)butanoate 
. . Y  
723 O-1064 N/A C26H44FNO; (5Z,8Z,11Z,14Z)-N-(2-Fluoroethyl)-2,16,16-
trimethylhenicosa-5,8,11,14-tetraenamide 
. . Y  
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724 O-1125 N/A C26H39NO3; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-N,N,6-trimethylheptanamide 
. . Y  
725 O-1238 N/A C22H29N3O2; (6aR,10aR)-3-[(2Z)-6-Azidohex-2-en-1-yl]-6,6,9-
trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
726 O-1248 N/A C19H17Cl3N4O; 7-Chloro-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-
indazole-3-carboxamide 
. . Y  
727 O-1269 N/A C22H22Cl3N3O; 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-
pentyl-1H-pyrazole-3-carboxamide 
. . Y  
728 O-1376 N/A C25H36O; 5′-Methyl-4-(2-methyloctan-2-yl)-2′-(propan-2-yl)[1,1′-
biphenyl]-2-ol 
. . Y  
729 O-1422 N/A C21H34O2; 2-Cyclohexyl-5-(2-methyloctan-2-yl)benzene-1,3-diol . . Y  
730 O-1424 N/A C20H32O2; 2-Cyclopentyl-5-(2-methyloctan-2-yl)benzene-1,3-diol . . Y  
731 O-1425 N/A C20H32O2S; 5-(2-Methyloctan-2-yl)-2-(thian-4-yl)benzene-1,3-diol . . Y  
732 O-1601 N/A C25H36O2; 5′-(Hydroxymethyl)-4-(2-methyloctan-2-yl)-2′-(propan-2-
yl)[1,1′-biphenyl]-2-ol 
. . Y  
733 O-1602 N/A C17H22O2; (1′R,2′R)-5′,6-Dimethyl-2′-(prop-1-en-2-yl)-1′,2′,3′,4′-
tetrahydro[1,1′-biphenyl]-2,4-diol 
. . Y  
734 O-1656 N/A C22H36O2; 2-Cycloheptyl-5-(2-methyloctan-2-yl)benzene-1,3-diol . . Y  
735 O-1658 N/A C22H36O2; 2-(2-Methylcyclohexyl)-5-(2-methyloctan-2-yl)benzene-1,3-
diol 
. . Y  
736 O-1660 N/A C25H38O2; 2-(Adamantan-2-yl)-5-(2-methyloctan-2-yl)benzene-1,3-diol . . Y  
737 O-1663 N/A C27H38O2; 14-(2-Methyloctan-2-yl)-21,22,23,24,25,26-
hexahydro[11,21:24,31-terphenyl]-12,16-diol 
. . Y  
738 O-1812 N/A C26H42N2O2; (5Z,8Z,11Z,14Z)-20-Cyano-N-[(2R)-1-hydroxypropan-2-
yl]-16,16-dimethylicosa-5,8,11,14-tetraenamide 
. . Y  
739 O-1826 N/A C22H36O2; 2-[(3S)-3-Methylcyclohexyl]-5-(2-methyloctan-2-
yl)benzene-1,3-diol 
. . Y  
740 O-1871 N/A C23H38O2; 2-(3,3-Dimethylcyclohexyl)-5-(2-methyloctan-2-yl)benzene-
1,3-diol 
. . Y  
741 O-1918 N/A C19H26O2; (1R,2R)-2′,6′-Dimethoxy-4′,5-dimethyl-2-(prop-1-en-2-yl)-
1,2,3,4-tetrahydro-1,1′-biphenyl 
. . Y  
742 O-1966 N/A C24H40O3; 1-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-3-
methylcyclohexan-1-ol 
. . Y  
743 O-2050 N/A C23H31NO4S; N-{6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]hex-4-yn-1-
yl}methanesulfonamide 
. . Y  
744 O-2113 N/A C25H39NO4S; N-{5-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-5-
methylhexyl}ethanesulfonamide 
. . Y  
745 O-2372 N/A C28H41NO4; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-6-methyl-1-(morpholin-4-
yl)heptan-1-one 
. . Y  
746 O-2373 N/A C29H43NO3; 6-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-6-methyl-1-(piperidin-1-
yl)heptan-1-one 
. . Y  
747 O-2545 N/A C26H36N2O2; (6aR,10aR)-3-[6-(1H-Imidazol-1-yl)-2-methylhexan-2-yl]-
6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
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748 O-2694 N/A C38H60N2O5; (6aR,10aR)-6,6,9-Trimethyl-3-[2-methyl-7-(morpholin-4-
yl)-7-oxoheptan-2-yl]-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-
yl 4-[di(propan-2-yl)amino]butanoate 
. . Y  
749 O-774 N/A C25H35NO2; 7-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-7-methyloctanenitrile 
. . Y  
750 O-806 N/A C22H27BrO2; (6aR,10aR)-3-(6-Bromohex-2-yn-1-yl)-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  
751 O-823 N/A C23H27NO2; 7-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]hept-5-ynenitrile 
. . Y  
752 ORG 27569 N/A C24H28ClN3O; 5-chloro-3-ethyl-1H-indole-2-carboxylic acid [2-(4-
piperidin-1-yl-phenyl)ethyl]amide 
Y Y Y  
753 ORG 27759 N/A C21H24FN3O; N-{2-[4-(dimethylamino)phenyl]ethyl}-3-ethyl-5-fluoro-
1H-indole-2-carboxamide 
Y Y Y  
754 ORG 28312 N/A C24H35N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][(3R,5S)-
3,4,5-trimethylpiperazin-1-yl]methanone 
. . Y  
755 ORG 28611 SCH-900,111; C23H33N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][(3S)-
3,4-dimethylpiperazin-1-yl]methanone 
. . Y  
756 ORG 29647 N/A C22H24ClN3O; (R)-N-(1-Benzylpyrrolidin-3-yl)-5-chloro-3-ethyl-1H-
indole-2-carboxamide fumarate 
Y Y Y  
757 ORTHO-RCS-4 RCS-2 C21H23NO2; (2-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone Y Y Y  
758 P-F-CUMYL-THPICA N/A C24H27FN2O2; N-[2-(4-Fluorophenyl)propan-2-yl]-1-[(oxan-4-
yl)methyl]-1H-indole-3-carboxamide 
. . Y  
759 PARAHEXYL  Synhexyl; n-hexyl-Δ3THC; n-Hexyl-D3-THC C22H32O2; 3-Hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-
dibenzo[b,d]pyran-1-ol 
. . Y  
760 PB-22 QUPIC; 1-Pentyl-8-quinolinyl ester-1H-in C23H22N2O2; 1-Pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester Y Y Y  
761 PB-22 N-(2-FLUOROPENTYL) N/A C23H21FN2O2; quinolin-8-yl 1-(2-fluoropentyl)-1H-indole-3-
carboxylate 
Y . .  
762 PB-22 N-(4-FLUOROPENTYL) N/A C22H20FN3O2; Quinolin-8-yl 1-(4-fluoropentyl)-1H-indazole-3-
carboxylate 
Y . .  
763 PENTENYL-CP 47,497 N/A C17H24O2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-(pent-4-en-1-yl)phenol . . Y  
764 PENTYL NAPHTHOYL BENZIMIDAZOLONE N/A C23H22N2O2; 1-(Naphthalene-1-carbonyl)-3-pentyl-1,3-dihydro-2H-
benzimidazol-2-one 
. . Y  
765 PENTYL NAPHTHOYL BENZOTHIAZOLE N/A C23H23NOS; (Naphthalen-1-yl)(3-pentyl-2,3-dihydro-1,3-benzothiazol-
2-yl)methanone 
. . Y  
766 PENTYL NAPHTHOYL PYRAZOLOPYRIDINE 6N N/A C22H21N3O; (Naphthalen-1-yl)(1-pentyl-1H-pyrazolo[3,4-c]pyridin-3-
yl)methanone 
. . Y  
767 PENTYL NAPHTHOYL PYRAZOLOPYRIDINE 7N N/A C22H21N3O; (Naphthalen-1-yl)(1-pentyl-1H-pyrazolo[3,4-b]pyridin-3-
yl)methanone 
. . Y  
768 PENTYL NAPHTHOYLIMIDAZOLE N/A C19H20N2O; (Naphthalen-1-yl)(1-pentyl-1H-imidazol-4-yl)methanone . . Y  
769 PENTYL NAPHTHOYLINDANE N/A C25H26O; (Naphthalen-1-yl)(3-pentyl-2,3-dihydro-1H-inden-1-
yl)methanone 
. . Y  
770 PENTYL-CP 47,497 N/A C17H26O2; 2-[(1S,3R)-3-Hydroxycyclohexyl]-5-pentylphenol . . Y  
771 PERROTTETINENE cis-PET C24H28O2; (6aS,10aR)-6,6,9-Trimethyl-3-(2-phenylethyl)-6a,7,8,10a-
tetrahydro-6H-dibenzo[b,d]pyran-1-ol 
. . Y  




. . Y  
Short Running Title of the Article Journal Name, 2014, Vol. 0, No. 0    43 
773 PF-3845 PF-3845; 1196109-52-0; PF3845; PF 3845 C24H23F3N4O2; N-(Pyridin-3-yl)-4-[(3-{[5-(trifluoromethyl)pyridin-2-
yl]oxy}phenyl)methyl]piperidine-1-carboxamide 
. . Y  




. . Y  
775 PIPISB [11C]PipISB C27H26FN3O3S; N-[(4-Fluorophenyl)methyl]-4-[3-(piperidin-1-yl)-1H-
indole-1-sulfonyl]benzamide 
. . Y  
776 PSB-SB-1202 N/A C23H26O4; 5-Methoxy-3-[(2-methoxyphenyl)methyl]-7-pentyl-2H-1-
benzopyran-2-one 
. . Y  
777 PSB-SB-487 N/A C26H32O4; 5-Hydroxy-3-[(2-hydroxyphenyl)methyl]-7-(2-methylnonan-
2-yl)-2H-1-benzopyran-2-one 
. . Y  
778 QMPSB N/A C22H22N2O4S; Quinolin-8-yl 4-methyl-3-(piperidine-1-
sulfonyl)benzoate 
. . Y  
779 QUINOLIN-8-YL 3-(AZEPANE-1-SULFONYL)BENZOATE N/A C22H22N2O4S; Quinolin-8-yl 3-(azepane-1-sulfonyl)benzoate . . Y  
780 QUINOLIN-8-YL 3-(PIPERIDINE-1-SULFONYL)BENZOATE N/A C21H20N2O4S; Quinolin-8-yl 3-(piperidine-1-sulfonyl)benzoate . . Y  
781 QUINOLIN-8-YL 4-METHYL-3-(MORPHOLINE-4-
SULFONYL)BENZOATE 
N/A C21H20N2O5S; Quinolin-8-yl 4-methyl-3-(morpholine-4-
sulfonyl)benzoate 
. . Y  
782 QUINOLIN-8-YL-1-BENZYL-1H-INDAZOLE-3-CARBOXYLATE N/A C24H17N3O2; Quinolin-8-yl-1-benzyl-1H-indazole-3-carboxylate Y . .  
783 QUINOLINYL FLUOROPENTYL FLUOROPHENYL PYRAZOLE 
CARBOXYLATE 
N/A C24H21F2N3O2; Quinolin-8-yl 1-(5-fluoropentyl)-5-(2-fluorophenyl)-
1H-pyrazole-3-carboxylate 
. . Y  
784 RCS-4 3-(4-Methoxybenzoyl)-1-pentylindole C21H23NO2; (4-methoxyphenyl)-(1-pentylindol-3-yl)methanone Y Y Y  
785 RIMONABANT Acomplia; SR141,716 C22H21Cl3N4O; 5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-
N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide 
Y . Y  
786 S-444,823 N/A C25H33N3O4S; 3-(2-{[1-(Cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-
octahydrocycloocta[b]pyridine-3-carbonyl]amino}-1,3-thiazol-4-
yl)propanoic acid 
. . Y  
787 SDB-002 APICA; SDB-001; UNII-HKU510FH74 C25H34N2O; N-[(Adamantan-1-yl)methyl]-1-pentyl-1H-indole-3-
carboxamide 
. . Y  
788 SDB-004 CHM-PICA C21H30N2O; N-(Cyclohexylmethyl)-1-pentyl-1H-indole-3-carboxamide . . Y  
789 SDB-005 N/A C23H21N2O2; 1-pentyl-1H-indazole-3- carboxylic-acid-naphthalen-1-yl 
ester 
Y Y Y  
790 SDB-006 N/A C21H24N2O; N-benzyl-1-pentyl-1H-indole-3-carboxamide Y Y Y  
791 SER-601 COR-167 C28H38N2O2; N-(Adamantan-1-yl)-4-oxo-1-pentyl-6-(propan-2-yl)-1,4-
dihydroquinoline-3-carboxamide 
. . Y  
792 SGT-10 N/A C25H28N2O2; 1-(Cyclohexylmethyl)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-
1H-inden-1-yl]-1H-indole-3-carboxamide 
. . Y  
793 SGT-100 N/A C24H31FN2O; N-(Adamantan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide 
. . Y  
794 SGT-101 N/A C21H22F2N2O; 1-(5-Fluoropentyl)-N-[(4-fluorophenyl)methyl]-1H-
indole-3-carboxamide 
. . Y  
795 SGT-108 N/A C20H19Cl2FN2O; N-(2,3-Dichlorophenyl)-1-(5-fluoropentyl)-1H-indole-
3-carboxamide 
. . Y  
796 SGT-12 (CHM) p-CN-JWH-018 C27H24N2O; 4-[1-(Cyclohexylmethyl)-1H-indole-3-
carbonyl]naphthalene-1-carbonitrile 
. . Y  
797 SGT-138 2AD-2NE1 C24H32N2O; N-(Adamantan-2-yl)-1-pentyl-1H-indole-3-carboxamide . . Y  
798 SGT-139 P-F-SDB-006 C21H23FN2O; N-[(4-Fluorophenyl)methyl]-1-pentyl-1H-indole-3-
carboxamide 
. . Y  
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799 SGT-142 cis-MYRTANYL-PINACA C23H33N3O; N-{[(2S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl]methyl}-1-
pentyl-1H-indazole-3-carboxamide 
. . Y  
800 SGT-147 N/A C24H27FN2O2; 1-(5-Fluoropentyl)-4-oxo-N-(2-phenylpropan-2-yl)-1,4-
dihydroquinoline-3-carboxamide 
. . Y  
801 SGT-148 CUMYL-DMBINACA C23H29N3O; -(3,3-Dimethylbutyl)-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
. . Y  
802 SGT-149 CUMYL-FUBINACA C24H22FN3O; 1-[(4-Fluorophenyl)methyl]-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
. . Y  
803 SGT-15 AM-2201 Methoxynaphtyl analog C25H24FNO2; [1-(5-Fluoropentyl)-1H-indol-3-yl](4-
methoxynaphthalen-1-yl)methanone 
. . Y  
804 SGT-150 CUMYL-MPMINACA C24H30N4O; 1-[(1-Methylpiperidin-2-yl)methyl]-N-(2-phenylpropan-2-
yl)-1H-indazole-3-carboxamide 
. . Y  
805 SGT-152 N/A C25H29N3O; 1-[(Bicyclo[2.2.1]heptan-2-yl)methyl]-N-(2-phenylpropan-
2-yl)-1H-indazole-3-carboxamide 
. . Y  
806 SGT-156 CUMYL-CHMICA C25H30N2O; 1-(Cyclohexylmethyl)-N-(2-phenylpropan-2-yl)-1H-indole-
3-carboxamide 
. . Y  
807 SGT-157 p-Cl-CUMYL-PINACA C22H26ClN3O; N-[2-(4-Chlorophenyl)propan-2-yl]-1-pentyl-1H-
indazole-3-carboxamide 
. . Y  
808 SGT-158 N/A C22H25ClFN3O; N-[2-(4-Chlorophenyl)propan-2-yl]-1-(5-fluoropentyl)-
1H-indazole-3-carboxamide 
. . Y  
809 SGT-16 5F-AB-001 C24H30FNO; (Adamantan-1-yl)[1-(5-fluoropentyl)-1H-indol-3-
yl]methanone 
Y . Y  
810 SGT-162 N/A C22H24FN3O; 1-(5-Fluoropentyl)-N-(1-phenylcyclopropyl)-1H-indazole-
3-carboxamide 
. . Y  
811 SGT-177 2AD-2NE1-6F C24H31FN2O; N-(Adamantan-2-yl)-6-fluoro-1-pentyl-1H-indole-3-
carboxamide 
. . Y  
812 SGT-18 EAM-2232 C26H24N2O; 5-[3-(4-Ethylnaphthalene-1-carbonyl)-1H-indol-1-
yl]pentanenitrile 
. . Y  
813 SGT-184 CUMYL-MEINACA C23H28N4O2; 1-[2-(Morpholin-4-yl)ethyl]-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
. . Y  
814 SGT-185 N/A C20H23N3O; N-(2-Phenylpropan-2-yl)-1-propyl-1H-indazole-3-
carboxamide 
. . Y  
815 SGT-186 N/A C23H29N3O; 1-Hexyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-
carboxamide 
. . Y  
816 SGT-187 N/A C24H31N3O; 1-Heptyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-
carboxamide 
. . Y  
817 SGT-188 CUMYL-THPICA C24H28N2O2; 1-[(Oxan-4-yl)methyl]-N-(2-phenylpropan-2-yl)-1H-
indole-3-carboxamide 
. . Y  




Y Y Y  
819 SGT-194 2AD-ATHPINACA; 2-Adamantyl-THPINACA C24H31N3O2; N-(Adamantan-2-yl)-1-[(oxan-4-yl)methyl]-1H-indazole-
3-carboxamide 
Y . Y  
820 SGT-197 N/A C22H23FN2O2; N-[(4-Fluorophenyl)methyl]-1-[(oxan-4-yl)methyl]-1H-
indole-3-carboxamide 
. . Y  
821 SGT-1A PNI-E C22H25NO; (3,4-Dimethylphenyl)(1-pentyl-1H-indol-3-yl)methanone . . Y  
822 SGT-20 4'-Cl-AM-2201; Cl-2201 C24H21ClFNO; (4-Chloronaphthalen-1-yl)[1-(5-fluoropentyl)-1H-indol-
3-yl]methanone 
Y . Y  
823 SGT-214 N/A C22H25FN2O2; 2-Phenylpropan-2-yl 1-(5-fluoropentyl)-1H-indazole-3-
carboxylate 
. . Y  
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824 SGT-22 C4-APINACA; (C4)-AKB48 C22H29N3O; N-(Adamantan-1-yl)-1-butyl-1H-indazole-3-carboxamide . . Y  
825 SGT-225-R BLKB-1 C21H25N3O; 1-Pentyl-N-[(1R)-1-phenylethyl]-1H-indazole-3-
carboxamide 
. . Y  
826 SGT-23 CUMYL-BINACA C21H25N3O; 1-Butyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-
carboxamide 
. . Y  
827 SGT-233 N/A C22H26F2N2O3S; 3-(4,4-Difluoropiperidine-1-sulfonyl)-4-methyl-N-(2-
phenylpropan-2-yl)benzamide 
. . Y  
828 SGT-234 CUMYL-PIPETINACA C24H30N4O; N-(2-Phenylpropan-2-yl)-1-[2-(piperidin-1-yl)ethyl]-1H-
indazole-3-carboxamide 
. . Y  
829 SGT-235 N/A C24H28F2N4O; 1-[2-(4,4-Difluoropiperidin-1-yl)ethyl]-N-(2-
phenylpropan-2-yl)-1H-indazole-3-carboxamide 
. . Y  
830 SGT-237 CUMYL-P7AICA C22H27N3O; 1-Pentyl-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-
b]pyridine-3-carboxamide 
. . Y  
831 SGT-240 N/A C25H30N2O2; 1-Pentyl-N-(4-phenyloxan-4-yl)-1H-indole-3-
carboxamide 
. . Y  
832 SGT-247 N/A C25H30N2O; 1-Pentyl-N-(1-phenylcyclopentyl)-1H-indole-3-
carboxamide 
. . Y  




Y Y Y  
834 SGT-250 N/A C23H28N2O; 2-Methyl-N-(1-pentyl-1H-indol-3-yl)-2-
phenylpropanamide 
. . Y  
835 SGT-255 N/A C23H28FN3O; 1-(5-Fluoropentyl)-N-(2-phenylbutan-2-yl)-1H-indazole-
3-carboxamide 
. . Y  
836 SGT-257 DMH-PINACA C22H35N3O; N-(2-Methyloctan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide 
. . Y  
837 SGT-259 N/A C22H27N3O2; 2-Oxo-3-pentyl-N-(2-phenylpropan-2-yl)-2,3-dihydro-1H-
benzimidazole-1-carboxamide 
. . Y  
838 SGT-260 N/A C24H27N3O; 1-Pentyl-3-[3-(2-phenylpropan-2-yl)-1,2,4-oxadiazol-5-yl]-
1H-indole 
. . Y  
839 SGT-263 CUMYL-5F-P7AICA; 5F-CUMYL-P7AICA C22H26FN3O; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
pyrrolo[2,3-b]pyridine-3-carboxamide 
Y Y Y  
840 SGT-27 (Indazole) JWH-122; THJ-122 C24H24N2O; (4-Methylnaphthalen-1-yl)(1-pentyl-1H-indazol-3-
yl)methanone 
. . Y  
841 SGT-30 (Indazole) EAM-2201 C25H25FN2O; (4-Ethylnaphthalen-1-yl)[1-(5-fluoropentyl)-1H-indazol-
3-yl]methanone 
. . Y  
842 SGT-35 (Indazole) JWH-081; THJ-081 C24H24N2O2; (4-Methoxynaphthalen-1-yl)(1-pentyl-1H-indazol-3-
yl)methanone 
. . Y  
843 SGT-37 ADAMANTYL-CHMINACA; AKB-CHM C25H33N3O; N-(Adamantan-1-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide 
Y Y Y  
844 SGT-38 (Indazole) JWH-210; THJ-210 C25H26N2O; (4-Ethylnaphthalen-1-yl)(1-pentyl-1H-indazol-3-
yl)methanone 
. . Y  
845 SGT-41 CUMYL-CHMINACA C24H29N3O; 1-(Cyclohexylmethyl)-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
. . Y  
846 SGT-42 CUMYL-THPINACA C23H27N3O2; 1-[(Oxan-4-yl)methyl]-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
Y Y Y  
847 SGT-43 N/A C25H24N2O2; (4-Methylnaphthalen-1-yl){1-[(oxan-4-yl)methyl]-1H-
indazol-3-yl}methanone 
. . Y  
848 SGT-46 N/A C20H20N2O4S; Quinolin-8-yl 4-methyl-3-[(propan-2-
yl)sulfamoyl]benzoate 
. . Y  
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849 SGT-47 N/A C21H29N3OS; 2-Methoxy-N-methyl-N-{[2-(1-pentyl-1H-indol-3-yl)-1,3-
thiazol-4-yl]methyl}ethan-1-amine 
. . Y  
850 SGT-48 PTI-1 C21H29N3S; N,N-Diethyl-2-(1-pentyl-1H-indol-3-yl)-4-
thiazolemethanamine 
Y Y Y  
951 SGT-49 PTI-2 C23H33N3OS; N-(2-Methoxyethyl)-N-{[2-(1-pentyl-1H-indol-3-yl)-1,3-
thiazol-4-yl]methyl}propan-2-amine 
. . Y  
852 SGT-5 N/A C24H25N3O; 3-(3-Benzyl-1,2,4-oxadiazol-5-yl)-1-(cyclohexylmethyl)-
1H-indole 
. . Y  
853 SGT-50 (CHM) JWH-122; CHM-122 C27H27NO; [1-(Cyclohexylmethyl)-1H-indol-3-yl](4-methylnaphthalen-
1-yl)methanone 
. . Y  
854 SGT-52 N/A C20H28FN3O; [(3S)-3,4-Dimethylpiperazin-1-yl][1-(5-fluoropentyl)-1H-
indol-3-yl]methanone 
. . Y  
855 SGT-53 N/A C22H33N3O; [(3R,5S)-4-Ethyl-3,5-dimethylpiperazin-1-yl](1-pentyl-1H-
indol-3-yl)methanone 
. . Y  
856 SGT-55 CUMYL-BICA C22H26N2O; 1-Butyl-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide 
Y Y Y  
857 SGT-56 CUMYL-PICA C23H28N2O; 1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide 
Y Y Y  
858 SGT-57 TMCP-PINACA C20H29N3O; 1-Pentyl-N-(2,2,3,3-tetramethylcyclopropyl)-1H-indazole-
3-carboxamide 
. . Y  
859 SGT-58 (THPM) PB-22; QUTHPIC C24H22N2O3; Quinolin-8-yl 1-[(oxan-4-yl)methyl]-1H-indole-3-
carboxylate 
. . Y  
860 SGT-59 CHP-PINACA C20H29N3O: N-Cycloheptyl-1-pentyl-1H-indazole-3-carboxamide . . Y  
861 SGT-60 p-F-CUMYL-PINACA C22H26FN3O; N-[2-(4-Fluorophenyl)propan-2-yl]-1-pentyl-1H-indazole-
3-carboxamide 
. . Y  
862 SGT-62 PRAM-2201; PR-2201 C27H28FNO; [1-(5-Fluoropentyl)-1H-indol-3-yl](4-propylnaphthalen-1-
yl)methanone 
. . Y  
863 SGT-64 N/A C23H26F2N2O; 1-(5-Fluoropentyl)-N-[2-(4-fluorophenyl)propan-2-yl]-
1H-indole-3-carboxamide 
. . Y  
864 SGT-65 N/A C22H25F2N3O; 1-(5-Fluoropentyl)-N-[2-(4-fluorophenyl)propan-2-yl]-
1H-indazole-3-carboxamide 
. . Y  
865 SGT-66 BENZYL-PINACA C20H23N3O; N-Benzyl-1-pentyl-1H-indazole-3-carboxamide . . Y  
866 SGT-67 CUMYL-5F-PICA; 5F-CUMYL-PICA C23H27FN2O; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide 
Y Y Y  
867 SGT-68 N/A C22H32FN3O; [(3R,5S)-4-Ethyl-3,5-dimethylpiperazin-1-yl][1-(5-
fluoropentyl)-1H-indol-3-yl]methanone 
. . Y  
868 SGT-69 ADB-TFBICA C19H24F3N3O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
(4,4,4-trifluorobutyl)-1H-indole-3-carboxamide 
. . Y  
869 SGT-70 ADB-THPICA  C21H29N3O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
[(oxan-4-yl)methyl]-1H-indole-3-carboxamide 
. . Y  
870 SGT-78 CUMYL-4CN-BINACA; CUMYL-CYBINACA C22H24N4O; 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-
carboxamide 
Y Y Y  
871 SGT-8 (CHM) 7-MeO-JWH-081 C28H29NO3; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl](4-
methoxynaphthalen-1-yl)methanone 
. . Y  
872 SGT-81 PROPYL-PINACA C16H23N3O; 1-Pentyl-N-propyl-1H-indazole-3-carboxamide . . Y  
873 SGT-83 PENTYL-PINACA C18H27N3O; N,1-Dipentyl-1H-indazole-3-carboxamide . . Y  
874 SGT-85 CHX-PINACA C19H27N3O; N-Cyclohexyl-1-pentyl-1H-indazole-3-carboxamide . . Y  
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875 SGT-86 2AD-AKB48; 2AD-APINACA C23H31N3O; N-(Adamantan-2-yl)-1-pentyl-1H-indazole-3-carboxamide . . Y  
876 SGT-87 DCBN-PINACA C20H21Cl2N3O; N-[(3,4-Dichlorophenyl)methyl]-1-pentyl-1H-indazole-
3-carboxamide 
. . Y  
877 SGT-88 THQ-PINACA C22H25N3O; (3,4-Dihydroquinolin-1(2H)-yl)(1-pentyl-1H-indazol-3-
yl)methanone 
. . Y  
878 SGT-9 N/A C26H30N2O; 1-(Cyclohexylmethyl)-N-[(1S)-1,2,3,4-
tetrahydronaphthalen-1-yl]-1H-indole-3-carboxamide 
. . Y  
879 SPICE Spice products: Spice Silver; Spice Gold C21H30O2; C25H38O3; C21H34O2; C24H23NO; C22H25NO2; ... . Y Y  
880 SR-144,528 N/A C29H34ClN3O; 5-(4-Chloro-3-methylphenyl)-1-[(4-
methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-1H-pyrazole-3-carboxamide 
. . Y  
881 STS-135 STS-135;5-fluoro-APICA C24H31FN2O; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-
carboxamide 
Y Y Y  
882 TEDALINIB GRC-10693 C19H21F2N3O; (4S,7R)-N-tert-Butyl-1-(2,4-difluorophenyl)-4,5,6,7-
tetrahydro-1H-4,7-methanoindazole-3-carboxamide 
. . Y  
883 THJ-018 N/A C23H22N2O; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone Y Y Y  




Y Y Y  
885 TINABINOL SP-119; Tinabinolum C23H34O2S; 5,5-Dimethyl-8-(3-methyloctan-2-yl)-1,2,3,5-
tetrahydrothiopyrano[2,3-c][1]benzopyran-10-ol 
. . Y  
886 TRANS-1-[2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL]-2-(3-
HYDROXYPROPYL)CYCLOHEXANE 
US 4371720 #1-23 C24H40O2;  2-[(1R,2S)-2-(3-Hydroxypropyl)cyclohexyl]-5-(2-
methyloctan-2-yl)phenol 
. . Y  
887 TRANS-CP 47,497-C8 trans CP 47,497-C8 homologue C22H36NO2; 2-((1S,3S)-3-hydroxycyclohexyl)-5-(2-methylnonan-2-
yl)phenol 
Y Y Y  




Y Y Y  
889 UR-144 TMCP-018; KM-X1; MN-001; YX-17 C21H29NO; (1-pentylindol-3-yl)-(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  
890 UR-144 N-(3-CHLOROPENTYL) N/A C21H28ClNO;  [1-(3-chloropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 
Y . .  
891 URB-447 N/A C25H21ClN2O; 2-[(1R,2S,5R)-5-Hydroxy-2-(2-
hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol 
Y . Y  
892 URB-532 FAAH Inhibitor I; URB532; CHEMBL76745 C18H21NO3; 4-(Benzyloxy)phenyl butylcarbamate . . Y  
893 URB-597 KDS-4103 C20H22N2O3; [3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate Y Y Y  
894 URB-602 N/A C19H21NO2; Cyclohexyl [1,1′-biphenyl]-3-ylcarbamate Y . Y  
895 URB-754 86672-58-4 C16H14N2O2; 6-Methyl-2-(p-tolylamino)-4H-benzo[d][1,3]oxazin-4-one Y Y Y  
896 URB-937 N/A C20H22N2O4; 3′-Carbamoyl-6-hydroxy[1,1′-biphenyl]-3-yl 
cyclohexylcarbamate 
. . Y  
897 US 4371720 #1-20 N/A C24H40O3; 2-[(1R,2S,5R)-5-Hydroxy-2-(2-hydroxypropyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
898 US 4371720 #1-24 N/A C25H42O3;  (1R,4S)-3-[2-Hydroxy-4-(2-methyloctan-2-yl)phenyl]-4-(3-
hydroxypropyl)cycloheptan-1-ol 
. . Y  
899 US 4371720 #1-26 N/A C27H45NO3; N-[(1R,4S)-3-[2-Hydroxy-4-(2-methyloctan-2-yl)phenyl]-4-
(3-hydroxypropyl)cycloheptyl]acetamide 
. . Y  
900 US 4371720 #1-28 N/A C24H38O3; (3R,4R)-3-[2-Hydroxy-4-(2-methyloctan-2-yl)phenyl]-4-(3-
hydroxypropyl)cyclohexan-1-one 
. . Y  
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901 US 4371720 #1-29 N/A C23H38O4; 2-[(1R,2R,5R)-5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-
{[(2S)-octan-2-yl]oxy}phenol 
. . Y  
902 US 4371720 #1-33 N/A C27H38O4; (1R,4S)-3-(2-Hydroxy-4-{[(2S)-5-phenylpentan-2-
yl]oxy}phenyl)-4-(3-hydroxypropyl)cycloheptan-1-ol 
. . Y  
903 US 4371720 #1-6 N/A C25H42O3; 2-[(1R,2R,5R)-5-Hydroxy-2-(4-hydroxybutyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
904 US 4371720 #1-7 N/A C26H44O3; 2-[(1R,2R,5R)-5-Hydroxy-2-(5-hydroxypentyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
905 US 4371720 #1-8 N/A C25H42O3; 2-[(1R,2R,5R)-5-Hydroxy-2-(3-methoxypropyl)cyclohexyl]-5-
(2-methyloctan-2-yl)phenol 
. . Y  
906 US 4371720 #2-5 N/A C22H36O3; 2-[(1S,3S,5R)-3-Hydroxy-5-(hydroxymethyl)cyclohexyl]-5-(2-
methyloctan-2-yl)phenol 
. . Y  
907 US 4939138 #2E N/A C27H25BrN2O3; (4-Bromonaphthalen-1-yl){(3R)-5-methyl-3-
[(morpholin-4-yl)methyl]-2,3-dihydro[1,4]oxazino[2,3,4-hi]indol-6-
yl}methanone 
. . Y  
908 US 4939138 #2I N/A C27H26N2O3; {5-Methyl-2-[(morpholin-4-yl)methyl]-2,3-
dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl}(naphthalen-1-yl)methanone 
. . Y  
909 US 5068234 #2J N/A C23H26N2O2; (4-Methoxyphenyl){1-[(1-methylpiperidin-2-yl)methyl]-
1H-indol-3-yl}methanone 
. . Y  
910 US 5068234 #2M N/A C21H21FN2O; (2-Fluorophenyl){1-[(1-methylpyrrolidin-2-yl)methyl]-1H-
indol-3-yl}methanone 
. . Y  
911 US 5292736 #10 N/A C27H27NO; 4-(2-{(1E)-2-Methyl-1-[(naphthalen-1-yl)methylidene]-1H-
inden-3-yl}ethyl)morpholine 
. . Y  
912 US 5292736 #13 N/A C24H27NO3; 4-(2-{(1E)-1-[(3,4-Dimethoxyphenyl)methylidene]-1H-
inden-3-yl}ethyl)morpholine 
. . Y  
913 US 5292736 #18 N/A C24H24N2O; 4-[(E)-{3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-
ylidene}methyl]-1H-indole 
. . Y  
914 US 5292736 #19 N/A C26H25NO2; 4-[(E)-{3-[2-(Morpholin-4-yl)ethyl]-1H-inden-1-
ylidene}methyl]naphthalen-1-ol 
. . Y  
915 US 5292736 #3 N/A C24H27NO2; 4-(2-{(1E)-1-[(4-Methoxyphenyl)methylidene]-2-methyl-
1H-inden-3-yl}ethyl)morpholine 
. . Y  
916 US 5292736 #8 N/A C27H27NO2; 4-(2-{(1E)-1-[(4-Methoxynaphthalen-1-yl)methylidene]-
1H-inden-3-yl}ethyl)morpholine 
. . Y  
917 US 5292736 #9 N/A C26H25NO; 4-(2-{(1E)-1-[(Naphthalen-1-yl)methylidene]-1H-inden-3-
yl}ethyl)morpholine 
. . Y  
918 US 6017919 #1-8 N/A C22H27NO4; (2E)-N-[(4-Hydroxyphenyl)methyl]-3-[4-methoxy-3-
(pentyloxy)phenyl]prop-2-enamide 
. . Y  
919 US 6017919 #5-2 N/A C24H27NO3; N-[2-(4-Hydroxyphenyl)ethyl]-4-(pentyloxy)naphthalene-
2-carboxamide 
. . Y  
920 US 6017919 #7-91 N/A C22H26N4O5; 7-Methoxy-2,4-dioxo-8-(pentyloxy)-N-[2-(pyridin-4-
yl)ethyl]-1,4-dihydroquinazoline-3(2H)-carboxamide 
. . Y  
921 US 6509352 #3-25 N/A C23H25FN2O4; N-[(4-Fluorophenyl)methyl]-7-methoxy-2-oxo-8-
(pentyloxy)-1,2-dihydroquinoline-3-carboxamide 
. . Y  
922 US 6930118 #8 N/A C22H23N3O; 3-(3-Benzyl-1,2,4-oxadiazol-5-yl)-1-pentyl-1H-indole . . Y  
923 US 7297796 #17 N/A C22H31BrN2O3S; 4-Bromo-3-(piperidine-1-sulfonyl)-N-[(1S,2S,4R)-
1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]benzamide 
. . Y  
924 US 7297796 #33 N/A C22H30N2O4S; N-(Adamantan-2-yl)-4-methyl-3-(morpholine-4-
sulfonyl)benzamide 
. . Y  
925 US 7297796 #36 N/A C19H26N2O4S; N-[(2R)-Bicyclo[2.2.1]heptan-2-yl]-4-methyl-3-
(morpholine-4-sulfonyl)benzamide 
. . Y  
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926 US 7297796 #7 N/A C22H31BrN2O3S; 4-Bromo-N-[(6,6-dimethylbicyclo[3.1.1]heptan-2-
yl)methyl]-3-(piperidine-1-sulfonyl)benzamide 
. . Y  
927 US 7297796 #76 N/A C21H32N2O4S; 4-Methyl-3-(morpholine-4-sulfonyl)-N-(3,3,5-
trimethylcyclohexyl)benzamide 
. . Y  
928 US 7297796 #9 N/A C18H19BrN2O4S; N-Benzyl-4-bromo-3-(morpholine-4-
sulfonyl)benzamide 
. . Y  
929 US 7304064 #14 N/A C25H37N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][(3R,5S)-
4-ethyl-3,5-dimethylpiperazin-1-yl]methanone 
. . Y  
930 US 7304064 #17A N/A C25H35N3O2; [1-(Cyclohexylmethyl)-7-methoxy-1H-indol-3-yl][(9aS)-
octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methanone 
. . Y  
931 US 7700634 #13 N/A C23H30N4OS; N-({3-[(3R)-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-
hi]indol-6-yl]-1,2,4-thiadiazol-5-yl}methyl)-N-ethylethanamine 
. . Y  
932 US 7700634 #15A N/A C22H29ClN4O2S; N-[(3-{7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-yl}-
1,2,4-thiadiazol-5-yl)methyl]-N-ethyl-2-methoxyethan-1-amine 
. . Y  
933 US 7700634 #20 N/A C25H34ClN3OS; N-({2-[7-Chloro-1-(cyclohexylmethyl)-1H-indol-3-yl]-
1,3-thiazol-4-yl}methyl)-N-(2-methoxyethyl)propan-2-amine 
. . Y  
934 US 7700634 #23D N/A C22H28ClN3O2S; N-[(2-{7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-yl}-
1,3-thiazol-4-yl)methyl]-2-methoxy-N-methylethan-1-amine 
. . Y  
935 US 7700634 #38 N/A C23H30N4OS; 1-(Cyclohexylmethyl)-7-methoxy-3-{5-[(pyrrolidin-1-
yl)methyl]-1,3,4-thiadiazol-2-yl}-1H-indole 
. . Y  
936 US 7763732 #10A N/A C27H37N5O3S; 1-[(3-{7-Ethyl-1-[(oxan-4-yl)methyl]-1H-indol-3-yl}-
1,2,4-thiadiazol-5-yl)methyl]-N-(2-hydroxyethyl)piperidine-4-
carboxamide 
. . Y  
937 US 7763732 #15 N/A C20H25ClN4O4S2; N-[(3-{7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-yl}-
1,2,4-thiadiazol-5-yl)methyl]-N-(2-hydroxyethyl)methanesulfonamide 
. . Y  
938 US 7772227 #10 N/A C26H37N3O3; [(3R)-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-
hi]indol-6-yl][(3R,5S)-4-(2-methoxyethyl)-3,5-dimethylpiperazin-1-
yl]methanone 
. . Y  
939 US 7772227 #12B N/A C23H31N3O; [(4S)-4-Cyclopentyl-5,6-dihydro-4H-pyrrolo[3,2,1-
ij]quinolin-1-yl](4-ethylpiperazin-1-yl)methanone 
. . Y  
940 US 7772227 #2 N/A C25H33N3O2; [(3R)-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-
hi]indol-6-yl][(9aS)-octahydro-2H-pyrido[1,2-a]pyrazin-2-yl]methanone 
. . Y  
941 US 7772227 #4 N/A C23H31N3O2; [(3R)-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-
hi]indol-6-yl][(3S)-3,4-dimethylpiperazin-1-yl]methanone 
. . Y  
942 US 7772227 #8 N/A C25H35N3O2; [(3R)-3-Cyclohexyl-2,3-dihydro[1,4]oxazino[2,3,4-
hi]indol-6-yl][(3R,5S)-4-ethyl-3,5-dimethylpiperazin-1-yl]methanone 
. . Y  
943 US 7820144 #2-28 N/A C21H21IN2O2; (2-Iodophenyl){1-[(4-methylmorpholin-3-yl)methyl]-1H-
indol-3-yl}methanone 
. . Y  
944 US 7820144 #2-31 N/A C25H24N2O2; {1-[(4-Methylmorpholin-3-yl)methyl]-1H-indol-3-
yl}(naphthalen-1-yl)methanone 
. . Y  
945 US 8106218 #3.4 N/A C25H33Cl2N3OS; 7-Chloro-1-(5-chloropentyl)-N-[(6,6-
dimethylbicyclo[3.1.1]heptan-2-yl)methyl]-4,5-dihydro-1H-thieno[2,3-
g]indazole-3-carboxamide 
. . Y  
946 VDM-11 VDM 11; 313998-81-1 C27H39NO2; (5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)icosa-
5,8,11,14-tetraenamide 
. . Y  
947 VIRODHAMINE O-arachidonoylethanolamine; O-AEA C22H37NO2; 2-Aminoethyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate . . Y  
948 WIN 48,098 Pravadoline; Pleconaril; 153168-05-9 C23H26N2O3; (4-Methoxyphenyl){2-methyl-1-[2-(morpholin-4-
yl)ethyl]-1H-indol-3-yl}methanone 
Y Y Y  
949 WIN 53,365 N/A C26H26N2O2; {2-Methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-
yl}(naphthalen-1-yl)methanone 
. . Y  
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950 WIN 54,461 6-Bromopravadoline C23H25BrN2O3; {6-Bromo-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-
indol-3-yl}(4-methoxyphenyl)methanone 
. . Y  
951 WIN 55,212-3 LSM-15495 C27H26N2O3;  {(3S)-5-Methyl-3-[(morpholin-4-yl)methyl]-2,3-
dihydro[1,4]oxazino[2,3,4-hi]indol-6-yl}(naphthalen-1-yl)methanone 
. . Y  
952 WIN 55212-2 WIN 55,212-2 C27H26N2O3; (11R)-2-methyl-11-[(morpholin-4-yl)methyl]-3-
(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.0⁴,¹²]dodeca-
2,4(12),5,7-tetraene 
Y Y Y  
953 WIN 56,098 N/A C30H28N2O2; (Anthracen-9-yl){2-methyl-1-[2-(morpholin-4-yl)ethyl]-
1H-indol-3-yl}methanone 
. . Y  
954 WO 1997/000860 #7 N/A C27H27BrN2O3; (4-Bromonaphthalen-1-yl){7-methoxy-2-methyl-1-[2-
(morpholin-4-yl)ethyl]-1H-indol-3-yl}methanone 
. . Y  
955 WO 1998/037061 #183 N/A C21H24NO3P; Methyl P-butyl-N-{4-[(naphthalen-1-
yl)oxy]phenyl}phosphonamidate 
. . Y  
956 WO 1998/037061 #216 N/A C22H26F3NO4S; 4-[(2-Propyl-1,2,3,4-tetrahydroisoquinolin-5-
yl)oxy]phenyl 4,4,4-trifluorobutane-1-sulfonate 
. . Y  
957 WO 1998/037061 #274 N/A C20H22F3NO4S; 4,4,4-Trifluoro-N-(3-{[(2R)-2-(hydroxymethyl)-2,3-
dihydro-1H-inden-4-yl]oxy}phenyl)butane-1-sulfonamide 
. . Y  
958 WO 1998/037061 #34 N/A C20H21NO3S; N-{3-[(Naphthalen-1-yl)oxy]phenyl}butane-1-
sulfonamide 
. . Y  
959 WO 1998/037061 #39 N/A C18H19N3O3S; N-{6-[(Quinolin-8-yl)oxy]pyridin-3-yl}butane-1-
sulfonamide 
. . Y  
960 WO 1998/037061 #51 N/A C23H19NO3S; N-{3-[(Naphthalen-1-yl)oxy]phenyl}-1-
phenylmethanesulfonamide 
. . Y  
961 WO 1998/037061 #90 N/A C20H21NO4S2; N-[4-(Naphthalene-1-sulfonyl)phenyl]butane-1-
sulfonamide 
. . Y  
962 WO 1998/037061 #92 N/A C21H23NO4S; N-(4-{[6-(Hydroxymethyl)naphthalen-1-
yl]oxy}phenyl)butane-1-sulfonamide 
. . Y  
963 WO 2000/010967 #1 N/A C19H17F3O6S; 3-{[2-(Hydroxymethyl)-1-benzofuran-7-yl]oxy}phenyl 
4,4,4-trifluorobutane-1-sulfonate 
. . Y  
964 WO 2001/058869 #109 N/A C22H34N4O3; (7S)-7-[(Morpholin-4-yl)methyl]-N-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-6,7-dihydro-5H-pyrazolo[5,1-
b][1,3]oxazine-2-carboxamide 
. . Y  
965 WO 2001/058869 #114 N/A C26H38N2O2; 7-Methoxy-2-methyl-1-pentyl-N-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-carboxamide 
. . Y  
966 WO 2001/058869 #122 N/A C29H36N2O3; 7-Methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indole-3-
carboxamide 
. . Y  
967 WO 2001/058869 #18 N/A C26H32N2O5; Methyl (2S)-2-{[6-methoxy-2-methyl-7-(pentyloxy)-1H-
indole-3-carbonyl]amino}-3-phenylpropanoate; Methyl N-[6-methoxy-
2-methyl-7-(pentyloxy)-1H-indole-3-carbonyl]-L-phenylalaninate 
. . Y  
968 WO 2001/058869 #184 N/A C21H25N3O3; 5-[(2-Methoxyphenyl)methyl]-1-[2-(morpholin-4-
yl)ethyl]-1,5-dihydro-4H-pyrrolo[3,2-c]pyridin-4-one 
. . Y  
969 WO 2001/058869 #189 N/A C26H34N2O2; 5-Butyl-6-methoxy-2-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-2,5-dihydro-1H-pyrido[4,3-b]indol-
1-one 
. . Y  
970 WO 2001/058869 #190 N/A C28H31N3O2; 6-Methoxy-5-[(pyridin-4-yl)methyl]-2-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-2,5-dihydro-1H-pyrido[4,3-b]indol-
1-one 
. . Y  
971 WO 2001/058869 #198 N/A C28H39N3O2; 2-Methyl-1-[2-(morpholin-4-yl)ethyl]-5-phenyl-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-pyrrole-3-
carboxamide 
. . Y  
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972 WO 2001/058869 #200 N/A C29H37N3O2; 1-[2-(Morpholin-4-yl)ethyl]-2-phenyl-5-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-1,5-dihydro-4H-pyrrolo[3,2-
c]pyridin-4-one 
. . Y  
973 WO 2001/058869 #204 N/A C22H26N4O3; N-Benzyl-7-methoxy-1-[2-(morpholin-4-yl)ethyl]-1H-
indazole-3-carboxamide 
. . Y  
974 WO 2001/058869 #216 N/A C24H28N4O4; N-[(1S,2R)-2-Hydroxy-2,3-dihydro-1H-inden-1-yl]-7-
methoxy-1-[2-(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide 
. . Y  
975 WO 2001/058869 #223 N/A C25H38N4O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-(2,2,6,6-
tetramethylcyclohexyl)-1H-indazole-3-carboxamide 
. . Y  




. . Y  
977 WO 2001/058869 #231 N/A C25H30N4O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[(1S)-1,2,3,4-
tetrahydronaphthalen-1-yl]-1H-indazole-3-carboxamide 
. . Y  
978 WO 2001/058869 #232 N/A C23H26N4O5; N-[(2H-1,3-Benzodioxol-5-yl)methyl]-7-methoxy-1-[2-
(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide 
. . Y  
979 WO 2001/058869 #256 N/A C26H36N4O3; N-[(Adamantan-1-yl)methyl]-7-methoxy-1-[2-
(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide 
. . Y  
980 WO 2001/058869 #261 N/A C25H38N4O3; 7-Methoxy-N-[(1R,2S,5R)-5-methyl-2-(propan-2-
yl)cyclohexyl]-1-[2-(morpholin-4-yl)ethyl]-1H-indazole-3-carboxamide 
. . Y  




. . Y  
982 WO 2001/058869 #280 N/A C20H28N4O4; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-{[(2R)-oxolan-
2-yl]methyl}-1H-indazole-3-carboxamide 
. . Y  
983 WO 2001/058869 #293 N/A C24H30N4O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-(2-
phenylpropan-2-yl)-1H-indazole-3-carboxamide 
. . Y  
984 WO 2001/058869 #30 N/A C23H28N4O2; 2-Methyl-1-[2-(morpholin-4-yl)ethyl]-N-[2-(pyridin-2-
yl)ethyl]-1H-indole-3-carboxamide 
. . Y  




. . Y  




. . Y  




. . Y  
988 WO 2001/058869 #391 N/A C21H31N5O3; (4-Ethylpiperazin-1-yl){7-methoxy-1-[2-(morpholin-4-
yl)ethyl]-1H-indazol-3-yl}methanone 
. . Y  
989 WO 2001/058869 #40 N/A C26H31N3O4; Methyl (2S)-2-({2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-
indole-3-carbonyl}amino)-3-phenylpropanoate; Methyl N-{2-methyl-1-
[2-(morpholin-4-yl)ethyl]-1H-indole-3-carbonyl}-L-phenylalaninate 
. . Y  
990 WO 2001/058869 #41 N/A C25H29N3O2; (3,4-Dihydroquinolin-1(2H)-yl){2-methyl-1-[2-
(morpholin-4-yl)ethyl]-1H-indol-3-yl}methanone 
. . Y  
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991 WO 2001/058869 #44 N/A C26H33N3O3; 7-Methoxy-2-methyl-N-[1-(4-methylphenyl)ethyl]-1-[2-
(morpholin-4-yl)ethyl]-1H-indole-3-carboxamide 
. . Y  
992 WO 2001/058869 #45 N/A C24H28N4O4; Methyl (2S)-2-({1-[2-(morpholin-4-yl)ethyl]-1H-indazole-
3-carbonyl}amino)-3-phenylpropanoate; Methyl N-{1-[2-(morpholin-4-
yl)ethyl]-1H-indazole-3-carbonyl}-L-phenylalaninate 
. . Y  
993 WO 2001/058869 #450 N/A C21H22Cl2N4O3; N-(2,3-Dichlorophenyl)-7-methoxy-1-[2-(morpholin-
4-yl)ethyl]-1H-indazole-3-carboxamide 
. . Y  
994 WO 2001/058869 #490 N/A C22H32N4O3; N-(Cyclohexylmethyl)-7-methoxy-1-[2-(morpholin-4-
yl)ethyl]-1H-indazole-3-carboxamide 
. . Y  
995 WO 2001/058869 #50 N/A C25H36N4O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-[(1S,2S,4R)-
1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-1H-indazole-3-carboxamide 
. . Y  
996 WO 2001/058869 #507 N/A C25H34N4O3; (3R)-3-[(Morpholin-4-yl)methyl]-N-[(1S,2S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl]-2,3-dihydro[1,4]oxazino[2,3,4-
hi]indazole-6-carboxamide 
. . Y  
997 WO 2001/058869 #55 N/A C25H26N4O3; 7-Methoxy-1-[2-(morpholin-4-yl)ethyl]-N-(naphthalen-1-
yl)-1H-indazole-3-carboxamide 
. . Y  




. . Y  
999 WO 2001/058869 #66 N/A C19H25N3O3; Methyl (2S)-2-[(1-pentyl-1H-imidazole-4-
carbonyl)amino]-3-phenylpropanoate; Methyl N-(1-pentyl-1H-
imidazole-4-carbonyl)-L-phenylalaninate 
. . Y  





. . Y  
1001 WO 2001/058869 #79 N/A C27H37N3O3; (3R)-5-Methyl-3-[(morpholin-4-yl)methyl]-N-[(1S,2S,4R)-
1,3,3-trimethylbicyclo[2.2.1]heptan-2-yl]-2,3-
dihydro[1,4]oxazino[2,3,4-hi]indole-6-carboxamide 
. . Y  
1002 WO 2001/064763 #63 N/A C15H16F3NO4S; 3-(4-Ethyl-1,3-oxazol-2-yl)phenyl 4,4,4-
trifluorobutane-1-sulfonate 
. . Y  
1003 WO 2002/042248 #109 N/A C27H25NO3; {4-[2-(Morpholin-4-yl)ethoxy]naphthalen-1-
yl}(naphthalen-1-yl)methanone 
. . Y  
1004 WO 2002/042248 #38 N/A C26H25NO3; Quinolin-8-yl 4-(hexyloxy)naphthalene-1-carboxylate . . Y  
1005 WO 2002/042248 #4 N/A C26H26O3S; 1-(Hexyloxy)-4-(naphthalene-1-sulfonyl)naphthalene . . Y  
1006 WO 2002/042269 #54 N/A C21H21Cl2NOS; (2,3-Dichlorophenyl){7-ethyl-1-[3-
(methylsulfanyl)propyl]-1H-indol-3-yl}methanone 
. . Y  
1007 WO 2003/035005 #1 N/A C24H32N4O2; N-(Adamantan-1-yl)-1-[2-(morpholin-4-yl)ethyl]-1H-
indazole-3-carboxamide 
. . Y  
1008 WO 2003/035005 #12 N/A C21H22IN3O; (2-Iodophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-
indazol-3-yl}methanone 
. . Y  
1009 WO 2003/035005 #2 N/A C25H34N4O; N-(Adamantan-1-yl)-1-[(1-methylpiperidin-2-yl)methyl]-
1H-indazole-3-carboxamide 
. . Y  
1010 WO 2003/035005 #3 N/A C23H28N4O; N-(Adamantan-1-yl)-1-(4-cyanobutyl)-1H-indazole-3-
carboxamide 
. . Y  
1011 WO 2003/035005 #4 N/A C22H28ClN3O; N-(Adamantan-1-yl)-1-(4-chlorobutyl)-1H-indazole-3-
carboxamide 
. . Y  
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1012 WO 2003/035005 #5 N/A C22H28IN3O; N-(Adamantan-1-yl)-1-(4-iodobutyl)-1H-indazole-3-
carboxamide 
. . Y  
1013 WO 2003/066603 #13 N/A C25H24N2O3; Ethyl 2-ethyl-5,7-dimethyl-3-(naphthalen-1-yl)-4-oxo-
3,4-dihydroquinazoline-6-carboxylate 
. . Y  
1014 WO 2003/066603 #2 N/A C24H28N4O8S; Ethyl 2-({[(2-hydroxyethyl)carbamoyl]oxy}methyl)-5,7-
dimethyl-3-[2-(methylsulfamoyl)phenyl]-4-oxo-3,4-dihydroquinazoline-
6-carboxylate 
. . Y  
1015 WO 2003/066603 #93 N/A C29H36N4O8S; Cyclobutylmethyl 2-({[(2-hydroxy-2-
methylpropyl)carbamoyl]oxy}methyl)-5,7-dimethyl-3-[2-
(methylsulfamoyl)phenyl]-4-oxo-3,4-dihydroquinazoline-6-carboxylate 
. . Y  
1016 WO 2004/108688 #8 N/A C26H39N3O2; [1-(Cyclohexylmethyl)-2-(2-methylbutan-2-yl)-1H-
benzimidazol-5-yl][(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone 
. . Y  
1017 WO 2005/016351 #10-030 N/A C26H29N3O2; 2-Oxo-N-[(1R)-1-phenylethyl]-1-[(pyridin-4-yl)methyl]-
1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamide 
. . Y  
1018 WO 2005/016351 #11-003 N/A C24H32N2O2; 1-(Cyclohexylmethyl)-5,6-dimethyl-2-oxo-N-(2-
phenylpropan-2-yl)-1,2-dihydropyridine-3-carboxamide 
. . Y  
1019 WO 2005/016351 #13-023 N/A C24H30N2O2; 1-Butyl-2-oxo-N-(2-phenylpropan-2-yl)-1,2,5,6,7,8-
hexahydro-5,8-methanoquinoline-3-carboxamide 
. . Y  
1020 WO 2005/016351 #13-030 N/A C26H30N2O2; 1-Butyl-5-methyl-2-oxo-6-phenyl-N-(2-phenylpropan-2-
yl)-1,2-dihydropyridine-3-carboxamide 
. . Y  
1021 WO 2005/016351 #13-044 N/A C22H28N2O3; 1-Butyl-2-oxo-N-(2-phenylpropan-2-yl)-1,5,7,8-
tetrahydro-2H-pyrano[4,3-b]pyridine-3-carboxamide 
. . Y  
1022 WO 2005/016351 #II-103 N/A C21H23N3S3; Prop-2-en-1-yl (8Z)-8-[(quinolin-5-yl)imino]-7-thia-9-
azaspiro[4.5]decane-9-carbodithioate 
. . Y  
1023 WO 2005/028456 #9 N/A C25H32N2OS; N-(Adamantan-1-yl)-4-pentyl-5-phenyl-1,3-thiazole-2-
carboxamide 
. . Y  
1024 WO 2006/129178 #294 N/A C24H23F2N3O; 1-(2,4-Difluorophenyl)-N-(2-phenylpropan-2-yl)-4,5,6,7-
tetrahydro-1H-4,7-methanoindazole-3-carboxamide 
. . Y  
1025 WO 2007/061360 #14 N/A C31H29N7O3; N-(Cyclobutylmethyl)-6-[(pyridin-2-yl)methoxy]-3-({4-
[(1H-1,2,3-triazol-1-yl)methyl]naphthalene-1-carbonyl}amino)pyridine-
2-carboxamide 
. . Y  
1026 WO 2008/032164 #13 N/A C20H30N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(3,3-
dimethylbutyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1027 WO 2008/032164 #132 N/A C20H28N4O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-
[(oxan-4-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1028 WO 2008/032164 #14 N/A C21H31N5O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(1-
methylpiperidin-2-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1029 WO 2008/032164 #152 N/A C18H26N4O3S; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-4-
methyl-3-[2-(methylsulfanyl)ethyl]-2-oxo-2,3-dihydro-1H-
benzimidazole-1-carboxamide 
. . Y  
1030 WO 2008/032164 #169 N/A C21H29FN4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-
(cyclohexylmethyl)-5-fluoro-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1031 WO 2008/032164 #176 N/A C21H31N3O3; 3-(Cyclohexylmethyl)-N-[(2S)-1-hydroxy-3,3-
dimethylbutan-2-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1032 WO 2008/032164 #188 N/A C24H27N3O3; 3-(Cyclohexylmethyl)-N-[(1S,2R)-2-hydroxy-2,3-dihydro-
1H-inden-1-yl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
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1033 WO 2008/032164 #199 N/A C23H27N3O2; 2-Oxo-3-pentyl-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-
yl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1034 WO 2008/032164 #200 N/A C21H30N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-
(cyclohexylmethyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1035 WO 2008/032164 #202 N/A C19H28N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-2-oxo-3-
pentyl-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1036 WO 2008/032164 #21 N/A C19H28N6O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[2-
(morpholin-4-yl)ethyl]-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-
carboxamide 
. . Y  
1037 WO 2008/032164 #217 N/A C20H28N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(2-
cyclobutylethyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1038 WO 2008/032164 #218 N/A C20H28N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(3-
cyclopropylpropyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1039 WO 2008/032164 #223 N/A C19H25N5O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-(4-
cyanobutyl)-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1040 WO 2008/032164 #231 N/A C19H22N6O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-2-oxo-3-
[(pyrimidin-4-yl)methyl]-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1041 WO 2008/032164 #233 N/A C18H22N6O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(5-
methyl-1,2,4-oxadiazol-3-yl)methyl]-2-oxo-2,3-dihydro-1H-
benzimidazole-1-carboxamide 
. . Y  
1042 WO 2008/032164 #238 N/A C19H23N5O3S; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(2-
methyl-1,3-thiazol-5-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1043 WO 2008/032164 #276 N/A C24H27N3O3; 3-[(Oxan-4-yl)methyl]-2-oxo-N-[(1S)-1,2,3,4-
tetrahydronaphthalen-1-yl]-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1044 WO 2008/032164 #292 N/A C18H26N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-butyl-
2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1045 WO 2008/032164 #293 N/A C18H23F3N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-2-oxo-
3-(4,4,4-trifluorobutyl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1046 WO 2008/032164 #304 N/A C21H27FN4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(4-
fluorocyclohex-3-en-1-yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-
1-carboxamide 
. . Y  
1047 WO 2008/032164 #306 N/A C21H28F2N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-
[(4,4-difluorocyclohexyl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-
1-carboxamide 
. . Y  
1048 WO 2008/032164 #311 N/A C21H25N3O4; N-[(2,5-Dimethylfuran-3-yl)methyl]-3-[(oxan-4-
yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1049 WO 2008/032164 #312 N/A C19H22N4O4; N-[(5-Methyl-1,2-oxazol-3-yl)methyl]-3-[(oxan-4-
yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1050 WO 2008/032164 #328 N/A C20H24N4O3S; N-[(2-Ethyl-1,3-thiazol-4-yl)methyl]-3-[(oxan-4-
yl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1051 WO 2008/032164 #348 N/A C21H24N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-
benzyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1052 WO 2008/032164 #357 N/A C21H23FN4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(2-
fluorophenyl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
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1053 WO 2008/032164 #359 N/A C22H24N6O3; N-[(1S)-1-(5-Amino-1,3,4-oxadiazol-2-yl)-2,2-
dimethylpropyl]-3-benzyl-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1054 WO 2008/032164 #363 N/A C21H23FN4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[(4-
fluorophenyl)methyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1055 WO 2008/032164 #4 N/A C20H29N5O4; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-3-[2-
(morpholin-4-yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carboxamide 
. . Y  
1056 WO 2008/032164 #47 N/A C23H28N4O3; 3-[2-(Morpholin-4-yl)ethyl]-2-oxo-N-(2-phenylpropan-2-
yl)-2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1057 WO 2008/032164 #5 N/A C21H30N4O5; Methyl (2S)-3,3-dimethyl-2-({3-[2-(morpholin-4-
yl)ethyl]-2-oxo-2,3-dihydro-1H-benzimidazole-1-
carbonyl}amino)butanoate 
. . Y  
1058 WO 2008/032164 #54 N/A C24H32N4O3; N-(Adamantan-1-yl)-3-[2-(morpholin-4-yl)ethyl]-2-oxo-
2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1059 WO 2008/032164 #73 N/A C24H24N4O3; 3-[2-(Morpholin-4-yl)ethyl]-N-(naphthalen-1-yl)-2-oxo-
2,3-dihydro-1H-benzimidazole-1-carboxamide 
. . Y  
1060 WO 2008/101995 #1 N/A C23H29ClN6O2S; 2-{4-[(3-{7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-3-
yl}-1,2,4-thiadiazol-5-yl)methyl]piperazin-1-yl}acetamide 
. . Y  
1061 WO 2008/101995 #24 N/A C25H33ClN6O4; 2-[(2S)-4-[(3-{7-Chloro-1-[(oxan-4-yl)methyl]-1H-indol-
3-yl}-1,2,4-oxadiazol-5-yl)methyl]-2-(hydroxymethyl)piperazin-1-yl]-N-
methylacetamide 
. . Y  
1062 WO 2008/152086 #1 N/A C25H33N3O; 3-Butyl-5,5-dimethyl-4-phenyl-N-(2-phenylpropan-2-yl)-
4,5-dihydro-1H-pyrazole-1-carboxamide 
. . Y  
1063 WO 2009/024819 #1-29 N/A C28H39N3O3; N-[4-(Cyclopropylamino)-4-oxobutyl]-N-ethyl-9-methyl-
3-(oxan-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide 
. . Y  
1064 WO 2009/037244 #101 N/A C25H36FN3O; 5-(2-Fluorophenyl)-1-pentyl-N-[(1R,2S,4R)-1,7,7-
trimethylbicyclo[2.2.1]heptan-2-yl]-4,5-dihydro-1H-pyrazole-3-
carboxamide 
. . Y  
1065 WO 2009/037244 #105 N/A C24H30FN3O; N-[2-(4-Fluorophenyl)propan-2-yl]-1-pentyl-5-phenyl-
4,5-dihydro-1H-pyrazole-3-carboxamide 
. . Y  
1066 WO 2009/106980 #1 N/A C18H23N5O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(3-
cyanopropyl)-1H-indazole-3-carboxamide 
. . Y  
1067 WO 2009/106980 #10 N/A C25H36N4O2; 1-(Cycloheptylmethyl)-N-[(2S)-1-(cyclopropylamino)-3,3-
dimethyl-1-oxobutan-2-yl]-1H-indazole-3-carboxamide 
. . Y  
1068 WO 2009/106980 #133 N/A C22H32N4O2; 1-(Cyclohexylmethyl)-N-[(2S)-3,3-dimethyl-1-
(methylamino)-1-oxobutan-2-yl]-1H-indazole-3-carboxamide 
. . Y  
1069 WO 2009/106980 #15 N/A C21H30N4O2; N-[(2S)-1-Amino-4-methyl-1-oxopentan-2-yl]-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide 
. . Y  
1070 WO 2009/106980 #173 N/A C23H32FN5O3; N-{(2S)-1-[(2-Amino-2-oxoethyl)amino]-3,3-dimethyl-1-
oxobutan-2-yl}-1-(cyclohexylmethyl)-5-fluoro-1H-indazole-3-
carboxamide 
. . Y  
1071 WO 2009/106980 #188 N/A C24H35FN4O3; 1-(Cyclohexylmethyl)-7-fluoro-N-{(2S)-1-[(3-
hydroxypropyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1072 WO 2009/106980 #2 N/A C17H21N5O2; N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(3-
cyanopropyl)-1H-indazole-3-carboxamide 
. . Y  
1073 WO 2009/106980 #249 N/A C19H23N7O2; N-[(1S)-1-(5-Amino-1,3,4-oxadiazol-2-yl)-2,2-
dimethylpropyl]-1-(3-cyanopropyl)-1H-indazole-3-carboxamide 
. . Y  
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1074 WO 2009/106980 #252 N/A C24H35FN4O3; 1-(Cyclohexylmethyl)-6-fluoro-N-{(2S)-1-[(3-
hydroxypropyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1075 WO 2009/106980 #305 N/A C26H34N6O6; Ethyl 5-({[(2S)-3,3-dimethyl-2-({1-[(oxan-4-yl)methyl]-
1H-indazole-3-carbonyl}amino)butanoyl]amino}methyl)-1,3,4-
oxadiazole-2-carboxylate 
. . Y  
1076 WO 2009/106980 #307 N/A C25H33N7O4; N-[(2S)-1-{[(5-Carbamoyl-1,3,4-oxadiazol-2-
yl)methyl]amino}-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide 
. . Y  
1077 WO 2009/106980 #333 N/A C25H26F3N5O5; N-{(2S)-1-[(2-Amino-2-oxoethyl)amino]-3,3-dimethyl-
1-oxobutan-2-yl}-1-{2-oxo-2-[4-(trifluoromethoxy)phenyl]ethyl}-1H-
indazole-3-carboxamide 
. . Y  
1078 WO 2009/106980 #342 N/A C25H37N5O4; 1-{2-[Cyclohexyl(methyl)amino]-2-oxoethyl}-N-{(2S)-1-
[(2-hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1079 WO 2009/106980 #387 N/A C24H31N7O5; N-[(2S)-1-{[(5-Carbamoyl-1,2,4-oxadiazol-3-
yl)methyl]amino}-3,3-dimethyl-1-oxobutan-2-yl]-1-[(oxan-4-yl)methyl]-
1H-indazole-3-carboxamide 
. . Y  
1080 WO 2009/106980 #4 N/A C21H21N5O2; N-[(2S)-1-Amino-1-oxo-3-phenylpropan-2-yl]-1-(3-
cyanopropyl)-1H-indazole-3-carboxamide 
. . Y  
1081 WO 2009/106980 #433 N/A C24H36N4O3; 1-(Cycloheptylmethyl)-N-{(2S)-1-[(2-
hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1082 WO 2009/106980 #435 N/A C21H27ClF2N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
chloro-1-[(4,4-difluorocyclohexyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1083 WO 2009/106980 #442 N/A C25H35N5O4; 1-(4-Cyanobutyl)-N-[(2S)-1-{[(4-hydroxyoxan-4-
yl)methyl]amino}-3,3-dimethyl-1-oxobutan-2-yl]-1H-indazole-3-
carboxamide 
. . Y  
1084 WO 2009/106980 #444 N/A C19H25F3N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
(5,5,5-trifluoropentyl)-1H-indazole-3-carboxamide 
. . Y  
1085 WO 2009/106980 #457 N/A C20H28N4O2S; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
[(thian-4-yl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1086 WO 2009/106980 #508 N/A C18H22F4N4O3; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
fluoro-1-[2-(2,2,2-trifluoroethoxy)ethyl]-1H-indazole-3-carboxamide 
. . Y  
1087 WO 2009/106980 #528 N/A C22H30N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
[(bicyclo[2.2.1]heptan-2-yl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1088 WO 2009/106980 #545 N/A C19H23F3N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
[(3,3-difluorocyclobutyl)methyl]-7-fluoro-1H-indazole-3-carboxamide 
. . Y  
1089 WO 2009/106980 #575 N/A C18H22F4N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
fluoro-1-(4,4,4-trifluorobutyl)-1H-indazole-3-carboxamide 
. . Y  
1090 WO 2009/106980 #586 N/A C21H25F4N5O2; 1-(4-Cyanobutyl)-N-{(2S)-3,3-dimethyl-1-oxo-1-[(2,2,2-
trifluoroethyl)amino]butan-2-yl}-7-fluoro-1H-indazole-3-carboxamide 
. . Y  
1091 WO 2009/106980 #6 N/A C19H28N4O3; N-[(2S)-1-Hydroxy-3,3-dimethylbutan-2-yl]-1-[(oxan-4-
yl)methyl]-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
. . Y  
1092 WO 2009/106980 #604 N/A C19H24F4N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
fluoro-1-(5,5,5-trifluoropentyl)-1H-indazole-3-carboxamide 
. . Y  
1093 WO 2009/106980 #610 N/A C20H29FN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(3,3-
dimethylbutyl)-7-fluoro-1H-indazole-3-carboxamide 
. . Y  
1094 WO 2009/106982 #11 N/A C25H26FN7O4; N-[(2S)-1-{[(5-Carbamoyl-1,3,4-oxadiazol-2-
yl)methyl]amino}-3,3-dimethyl-1-oxobutan-2-yl]-1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
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1095 WO 2009/106982 #12 N/A C20H23N5O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
benzyl-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
. . Y  
1096 WO 2009/106982 #170 N/A C21H22F2N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-5-
fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1097 WO 2009/106982 #171 N/A C24H26F2N4O2; N-[(2S)-1-(Cyclopropylamino)-3,3-dimethyl-1-
oxobutan-2-yl]-5-fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carboxamide 
. . Y  
1098 WO 2009/106982 #172 N/A C23H26F2N4O3; 5-Fluoro-1-[(4-fluorophenyl)methyl]-N-{(2S)-1-[(2-
hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1099 WO 2009/106982 #175 N/A C21H22F2N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1100 WO 2009/106982 #176 N/A C24H26F2N4O2; N-[(2S)-1-(Cyclopropylamino)-3,3-dimethyl-1-
oxobutan-2-yl]-7-fluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carboxamide 
. . Y  
1101 WO 2009/106982 #177 N/A C23H26F2N4O3; 7-Fluoro-1-[(4-fluorophenyl)methyl]-N-{(2S)-1-[(2-
hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1102 WO 2009/106982 #181 N/A C21H22ClFN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-7-
chloro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1103 WO 2009/106982 #183 N/A C23H26ClFN4O3; 7-Chloro-1-[(4-fluorophenyl)methyl]-N-{(2S)-1-[(2-
hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1104 WO 2009/106982 #226 N/A C21H21Cl2FN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-5,7-
dichloro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1105 WO 2009/106982 #247 N/A C25H29FN4O4; N-{(2S)-1-[(3R,4R)-3,4-Dihydroxypyrrolidin-1-yl]-3,3-
dimethyl-1-oxobutan-2-yl}-1-[(4-fluorophenyl)methyl]-1H-indazole-3-
carboxamide 
. . Y  
1106 WO 2009/106982 #282 N/A C21H21F3N4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-6,7-
difluoro-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1107 WO 2009/106982 #3 N/A C23H19FN4O2; N-[(1S)-2-Amino-2-oxo-1-phenylethyl]-1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1108 WO 2009/106982 #33 N/A C21H23BrN4O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
benzyl-6-bromo-1H-indazole-3-carboxamide 
. . Y  
1109 WO 2009/106982 #330 N/A C24H25F3N4O2; N-[(2S)-1-(3,3-Difluoroazetidin-1-yl)-3,3-dimethyl-1-
oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1110 WO 2009/106982 #336 N/A C24H26F2N4O2; N-[(2S)-1-(3-Fluoroazetidin-1-yl)-3,3-dimethyl-1-
oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1111 WO 2009/106982 #6 N/A C20H23N5O2; N-[(2S)-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-
[(pyridin-2-yl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1112 WO 2009/106982 #81 N/A C23H27FN4O3; 1-[(4-Fluorophenyl)methyl]-N-{(2S)-1-[(2-
hydroxyethyl)amino]-3,3-dimethyl-1-oxobutan-2-yl}-1H-indazole-3-
carboxamide 
. . Y  
1113 WO 2009/106982 #99 N/A C26H32FN5O4S; N-[(2S)-1-({2-
[(Cyclopropanesulfonyl)amino]ethyl}amino)-3,3-dimethyl-1-oxobutan-
2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
. . Y  
1114 WO 2011/025541 #455 N/A C20H21F2N3O3; (4aS,5aS)-1-(2,4-Difluorophenyl)-N-[4-
(hydroxymethyl)oxan-4-yl]-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide 
. . Y  
58    Journal Name, 2014, Vol. 0, No. 0 Principal Author Last Name  et al. 
1115 WO 2011/025541 #493 N/A C18H19F2N3O2; (4aS,5aS)-1-(2,4-Difluorophenyl)-N-(1-hydroxy-2-
methylpropan-2-yl)-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide 
. . Y  
1116 WO 2011/025541 #634 N/A C21H24F2N4O2; (4aS,5aS)-1-(2,4-Difluorophenyl)-N-[(2S)-3,3-dimethyl-
1-(methylamino)-1-oxobutan-2-yl]-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide 
. . Y  
1117 WO 2011/025541 #667 N/A C19H24N6O2; (4aS,5aS)-N-[(2S)-3,3-Dimethyl-1-(methylamino)-1-
oxobutan-2-yl]-1-(pyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide 
. . Y  
1118 WO 2011/025541 #921 N/A C21H19N5O3; (4aS,5aS)-N-[(1S,2R)-2-Hydroxy-2,3-dihydro-1H-inden-1-
yl]-1-(4-oxo-4λ5-pyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide 
. . Y  
1119 WO 2011/025541 #927 N/A C16H16F3N5O; (4aS,5aS)-1-(Pyrazin-2-yl)-N-(1,1,1-trifluoro-2-
methylpropan-2-yl)-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide 
. . Y  
1120 WO 2012/116278 #699 N/A C18H23N5O3; (4aS,5aS)-N-[(2S)-1-Hydroxy-3,3-dimethylbutan-2-yl]-1-
(4-oxo-4λ5-pyrazin-2-yl)-4,4a,5,5a-tetrahydro-1H-
cyclopropa[4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide  
. . Y  
1121 WO 2014/015298 #12 N/A C28H27NO; 4-(2-{(1E)-1-[(1,2-Dihydroacenaphthylen-5-
yl)methylidene]-1H-inden-3-yl}ethyl)morpholine 
. . Y  
1122 WO 2014/015298 #13 N/A C30H27NO; 4-(2-{(1E)-1-[(Phenanthren-4-yl)methylidene]-1H-inden-3-
yl}ethyl)morpholine 
. . Y  
1123 WO 2014/015298 #23 N/A C22H22INO; 4-(2-{(1E)-1-[(2-Iodophenyl)methylidene]-1H-inden-3-
yl}ethyl)morpholine 
. . Y  
1124 WO 2014/015298 #54 N/A C26H27NO3; Methyl 4-(1-pentyl-1H-indole-3-carbonyl)-4a,8a-
dihydronaphthalene-1-carboxylate 
. . Y  
1125 WO 2014/015298 #61 N/A C27H27NO2; 1-[4-(1-Pentyl-1H-indole-3-carbonyl)naphthalen-1-
yl]propan-1-one 
. . Y  
1126 WO 2014/015298 #62 N/A C24H22FNO; (4-Fluoro-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
1027 WO 2014/015298 #63 N/A C24H22FNO; (5-Fluoro-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
1128 WO 2014/015298 #64 N/A C24H22FNO; (6-Fluoro-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
1129 WO 2014/015298 #65 N/A C24H22FNO; (7-Fluoro-1-pentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone 
. . Y  
1130 WO 2014/015298 #66 N/A C24H21F2NO; [4-Fluoro-1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-
1-yl)methanone 
. . Y  
1131 WO 2014/015298 #67 N/A C27H28FNO; (4-Fluoro-1-pentyl-1H-indol-3-yl)(4-propylnaphthalen-1-
yl)methanone 
. . Y  
1132 WO 2014/015298 #8 N/A C28H29NO; 4-(2-{(1E)-1-[(4-Ethylnaphthalen-1-yl)methylidene]-1H-
inden-3-yl}ethyl)morpholine 
. . Y  
1133 WO 2014/015298 #9 N/A C29H31NO; 4-(2-{(1E)-1-[(4-Propylnaphthalen-1-yl)methylidene]-1H-
inden-3-yl}ethyl)morpholine 
. . Y  
1134 WO 2014/039042 #1.10 N/A C26H34N2O4; 3-(1H-Imidazol-1-yl)propyl 2-[(6aR,10aR)-1-hydroxy-
6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1135 WO 2014/039042 #1.19 N/A C26H33NO4; 4-Cyanobutyl 1-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]cyclobutane-1-
carboxylate 
. . Y  
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1136 WO 2014/039042 #1.3 N/A C25H33NO4; 4-Cyanobutyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1137 WO 2014/039042 #1.30 N/A C23H32O3S; S-Propyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanethioate 
. . Y  
1138 WO 2014/039042 #1.31 N/A C25H37NO3; 2-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methyl-N-pentylpropanamide 
. . Y  
1139 WO 2014/039042 #1.33 N/A C25H36O4; 2-[(6aR,10aR)-1-Hydroxy-6,6,9-trimethyl-6a,7,10,10a-
tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-methylpropyl pentanoate  
. . Y  
1140 WO 2014/039042 #1.8 N/A C24H31NO4; 3-Cyanopropyl 2-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1141 WO 2014/039042 #2.2 N/A C24H34O5; Butyl 2-[(6aR,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-
dimethyl-6a,7,10,10a-tetrahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1142 WO 2014/039042 #2.5 N/A C24H31NO5; 3-Cyanopropyl 2-[(6aR,10aR)-1-hydroxy-9-
(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-
dibenzo[b,d]pyran-3-yl]-2-methylpropanoate 
. . Y  
1143 WO 2014/039042 #2.7 N/A C27H39NO6; 3-(Morpholin-4-yl)propyl 2-[(6aR,10aR)-1-hydroxy-9-
(hydroxymethyl)-6,6-dimethyl-6a,7,10,10a-tetrahydro-6H-
dibenzo[b,d]pyran-3-yl]-2-methylpropanoate 
. . Y  
1144 WO 2014/039042 #3.4 N/A C23H32O5; Butyl 2-[(6aR,10aR)-1-hydroxy-6,6-dimethyl-9-oxo-
6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1145 WO 2014/039042 #3.6 N/A C23H34O5; Butyl 2-[(6aR,9R,10aR)-1,9-dihydroxy-6,6-dimethyl-
6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1146 WO 2014/039042 #3.9 N/A C24H36O5; Butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-
dimethyl-6a,7,8,9,10,10a-hexahydro-6H-dibenzo[b,d]pyran-3-yl]-2-
methylpropanoate 
. . Y  
1147 WO 2014/167530 #MJ10 N/A C28H33N3O; 1-[(Adamantan-2-yl)methyl]-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
. . Y  
1148 WO 2014/167530 #MJ2 N/A C22H33N3O; N-(2-Cyclohexylpropan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide 
. . Y  
1149 WO 2014/167530 #MJ7 N/A C24H27F2N3O; 1-[(4,4-Difluorocyclohexyl)methyl]-N-(2-phenylpropan-
2-yl)-1H-indazole-3-carboxamide 
. . Y  
1150 WO 2014/167530 #MJ8 N/A C25H31N3O; 1-(Cycloheptylmethyl)-N-(2-phenylpropan-2-yl)-1H-
indazole-3-carboxamide 
. . Y  
1151 XLR-11 5-F-UR-144 C21H28FNO; [1-(5-fluoropentyl)indol-3-yl]-(2,2,3,3-
tetramethylcyclopropyl)methanone 
Y Y Y  




Y . .  




Y . .  




Y . .  
1155 XLR-12 UNII-8F8H9MH5WP; 8F8H9MH5WP C20H24F3NO; (2,2,3,3-Tetramethylcyclopropyl)[1-(4,4,4-trifluorobutyl)-
1H-indol-3-yl]methanone 
Y . Y  
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